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Abstract 
Medicine continues to move towards less invasive techniques for many cardiac 
conditions, especially for high-risk patients that may not tolerate the alternative, more invasive 
approach.  For instance, patients born with the congenital heart defect hypoplastic left heart 
syndrome often require emergent creation of a perforation through the atrial septum for survival 
prior to palliative surgery. However, most approaches are catheter based, still invasive, and 
continue to have significant challenges, limitations, and complications.  A completely non-
invasive technique such as histotripsy may provide the same result in a faster, safer, and more 
efficient manner. Using high-pressure ultrasound pulses applied outside the body and focused to 
the targeted tissue, histotripsy generates a cluster of micro-bubbles and the energetic growth and 
collapse of these micro-bubbles results in fractionation of the target tissue. Histotripsy has been 
demonstrated successful for non-invasive tissue fractionation in various organs. The goal of this 
work is to investigate the safety and efficacy of histotripsy for neonatal cardiac applications. To 
aid in this goal, therapy guidance and monitoring techniques are developed, and an integrated 
histotripsy therapy system, optimized for the human neonate with congenital heart disease, was 
designed and constructed. 
In this dissertation, histotripsy is first demonstrated to be capable of generating targeted 
intra-cardiac communications when positioned outside the body in an intact neonatal animal 
model with minimal collateral damage or systemic side-effects. Moreover, further study showed 
no intermediate-term clinical, pathologic, and systemic effects of these intra-cardiac 
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communications created by histotripsy. Second, to mitigate the possibility of unintended injury 
due to heart motion, real-time motion correction using ultrasound imaging is developed and 
integrated into a histotripsy therapy system. This motion correction is developed specifically for 
the high-speed motions present in a beating heart. The performance of the motion correction is 
quantified in vitro and a validated in a single in vivo experiment. Third, to maximize therapy 
efficacy, novel bubble-induced color Doppler feedback is developed to monitor the degree of 
tissue damage during histotripsy treatment. Strong correlations existed between the quantitative 
metrics derived from the bubble-induced color Doppler and the degree of tissue fractionation as 
examined with histology, demonstrating the feasibility of using this technique as quantitative, 
real-time feedback for histotripsy treatments. Finally, a histotripsy therapy transducer with 
appropriate physical dimensions and acoustic parameters to precisely ablate cardiac tissue non-
invasively in a human neonate is developed and integrated into an ultrasound guided histotripsy 
therapy system. The data and the integrated system accomplished from this dissertation form the 
essential foundation to a pioneering clinical trial for histotripsy cardiac therapy in infants, which 
will position histotripsy for application on a broad range of cardiac disorders in patients of all 
ages.
 1 
 
Chapter 1 
Introduction 
The main goal of this study is to develop an ultrasound image guided histotripsy system 
optimized for safe and effective neonatal cardiac intervention. The safety and effectiveness of 
cardiac histotripsy will be demonstrated in a live animal model. To aid in this goal, therapy 
guidance and monitoring techniques are developed in parallel. These techniques are: (1) a real-
time motion correction system to lock the therapy focus onto the intended target as it is displaced 
by both cardiac and respiratory motion and (2) a method to capture real-time Doppler 
information during therapy to monitor and assess therapy progression. Finally, a histotripsy 
therapy transducer with appropriate physical dimensions and acoustic parameters to precisely 
ablate cardiac tissue non-invasively in a human neonate is developed and integrated into a 
complete ultrasound guided histotripsy therapy system. We anticipate that these studies will lead 
to the first clinical trial for histotripsy cardiac therapy in infants, positioning histotripsy to 
transform non-invasive therapy for a broad range of cardiac disorders in patients of all ages. 
Some examples of potential cardiac applications include: de-bulking obstructive tissues like 
those found in patients with Hypertrophic Cardiomyopathy (HCM), the induction of coronary 
artery thrombolysis, and the ablation of cardiac arrhythmias.  This would effectively 
revolutionize the clinical arsenal available for cardiac intervention, which is the ultimate goal of 
this line of research. 
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This chapter will first give a brief overview of histotripsy therapy and its application on 
cardiac tissues. This will be followed by an overview of the targeted clinical application of this 
work, the non-invasive creation of an atrial septal defect (ASD) in neonatal patients born with 
the congenital heart defect hypoplastic left heart syndrome (HLHS). The significance of this 
work will then be discussed, specifically the broad range of cardiac disorders with treatments 
that could potentially be enabled by this research. This chapter will then be concluded with an 
outline of the dissertation, including an overview of each chapter. 
 
1.1 Histotripsy Therapy 
Histotripsy is a form of cavitation-based ultrasound therapy that precisely fractionates 
and removes tissue [1-3], which can be used as a non-invasive alternative to the surgical removal 
of unwanted tissue for high-risk surgical patients with a wide variety of cardiac conditions. 
Histotripsy produces and controls a dense cluster of cavitation micro-bubbles (“bubble cloud”) 
[4-6] using specific ultrasound pulse sequences [7-9] to create pressures that exceed the 
cavitation threshold [10], causing mechanical cellular disruption at the focus [1-3, 11].  The 
process is typically guided and monitored in real-time using ultrasound imaging [2, 12], and has 
been shown capable of creating an ASD in vivo [13]. 
Extra-cardiac high intensity focused ultrasound (HIFU) has previously been used to 
generate thermal lesions to treat arrhythmia, where the HIFU transducer is placed directly 
outside the heart wall to produce lesions in cardiac tissue [14-16]. For example, the Epicor 
Cardiac Ablation System has been demonstrated to be a less invasive and effective alternative to 
treat human patients with atrial fibrillation (AF) [14, 17]. However, currently there are no 
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completely non-invasive techniques, apart from pharmacotherapy, for the treatment of congenital 
or acquired heart disease.  
Unlike HIFU thermal therapy, histotripsy precisely produces and controls a cavitation 
bubble cloud to fractionate tissue to liquid-appearing acellular homogenate [1, 18], which can be 
reabsorbed and eliminated by the body to achieve effective tissue remodeling and removal [11-
13]. Using microsecond long, high amplitude, shockwave ultrasound pulses separated by long 
intervals, cavitation bubble dynamics are controlled, while thermal injury to surrounding and 
intervening tissue can be avoided [7]. As bubbles are readily detected acoustically, the entire 
process is monitored and guided by real-time ultrasound imaging. In comparison to thermal 
therapy, histotripsy is more resistant to the aberration effect from bone and can be used to 
generate precise lesions through bone obstructions and over long intervening tissue paths [19]. A 
non-invasive approach like histotripsy has the potential to not only eliminate the risks and 
complications associated with conventional cardiopulmonary bypass, cardiac surgery and 
invasive catheterization but also improve overall outcome by providing a new clinical tool with 
unique applications.  From the fetus to the adult, non-invasive tissue perforation, discrete lesion 
creation, and/or bulk tissue removal would be revolutionary and transform clinical care for 
cardiac diseases.  
 
1.2 Targeted Clinical Application  
Medicine continues to move towards less invasive techniques for many cardiac 
conditions, especially for high-risk patients that may not tolerate the alternative, more invasive 
approach.  However, most approaches are catheter based, still invasive, and continue to have 
significant challenges, limitations, and complications.  A completely non-invasive technique 
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such as histotripsy may provide the same result in a faster, safer, and more efficient manner.  For 
instance, patients born with HLHS and an intact atrial septum require emergent creation of a 
perforation through the atrial septum (ASD) for survival prior to palliative surgery, and have 
increased risk (mortality 50-80%) compared to those born with an ASD [20-22].  Unfortunately, 
secondary to anatomic considerations and hemodynamic instability, current procedures are 
associated with very high morbidity and mortality, creating a clinical need for an entirely non-
invasive approach [21-23].  This high-risk population is well suited to establish the safety and 
therapeutic efficacy of histotripsy for cardiac applications. 
Current approaches to ASD creation in this patient group are fraught with challenges, 
limitations, and complications dictated by the clinical instability of these patients and their 
complicated anatomy (i.e. thick atrial septum and small left atrium), hence revealing a clinical 
need for an alternative approach [21, 24].  Because it permanently removes tissue, does not 
require vascular access (limits risk of infection, etc.) or fluoroscopy, and could potentially be 
done at the bedside, histotripsy would provide safer and timelier therapy thereby improving 
outcomes.  Based on this unmet clinical need, the overwhelming enthusiasm of this application 
within the Pediatric Cardiology community, and an optimal subcostal acoustic window (free of 
rib obstruction to a relatively immobile atrial septum) [13], we will first prepare histotripsy for 
non-invasive ASD creation in patients with HLHS.  Since the patient population is small and 
very high risk, histotripsy will qualify for designation as a Humanitarian Use Device making 
progression through external and internal regulatory approval and eventually into clinical use 
more efficiently and timely, especially compared to other applications.   
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1.3  Clinical Significance and Implications 
Once the clinical efficacy and safety of the technique are demonstrated in this initial 
pediatric population, the applications of histotripsy can be broadened through the technical 
advancements developed here to numerous other cardiac conditions in children and adults, 
validating it as an innovative clinical resource. There are a number of common cardiac 
conditions in which ultrasound-mediated tissue removal or remodeling may have important 
applications. Below are just a few diseases that may benefit from histotripsy therapy. 
Patients with hypertrophic cardiomyopathy (HCM), a condition that affects 1 in 500 
adults, often have significant obstruction below the aortic valve caused by excess muscle [25-29]. 
For patients deemed poor operative candidates due to other cardiac or non-cardiac conditions, 
alcohol septal ablation (which requires an infusion of alcohol into the coronary artery to create a 
septal infarction) [25, 30] has been used to remodel the tissue and relieve obstruction. 
Unfortunately, this less invasive approach has a relatively high frequency of serious 
complications including coronary artery perforation, complete heart block and ventricular 
arrhythmias [31, 32].  Non-invasive removal of tissue using histotripsy may prove to be a 
substantial advance for HCM patients who are poor candidates for surgery. 
Atrial fibrillation (AF) is a common condition affecting nearly 2 million people in the US 
[33-35].  Catheter-based procedures such as radiofrequency-mediated isolation of the pulmonary 
veins are associated with significant risk of atrial perforation or pulmonary venous obstruction 
[36]. Concurrent visualization and tissue modification using histotripsy may lead to comparable 
rates of success with lower risk of complications. 
Pulmonary hypertension (PHTN) is a less common but devastating condition that consists 
of high blood pressure in the lungs and failure of the right side of the heart. Despite improved 
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medical therapy some patients progress to need either lung transplantation (a high risk procedure 
with poor survival), or ASD creation (which can help maintain cardiac output and improve 
symptoms but has a significant surgical risk) [37, 38]. In this high-risk patient group, non-
invasive creation of a permanent ASD using histotripsy may be a low-risk, non-invasive way to 
significantly improve symptoms. A non-invasive approach to create an ASD also has important 
implications for another congenital heart condition, d-transposition of the great arteries (d-TGA) 
[39-41]. This condition often requires augmented mixing of blood at the atrial level (through the 
creation or enlargement of an ASD) prior to surgical repair. Furthermore, creation of new intra-
cardiac pathways in the developing fetus has exciting potential to lessen the severity of selected 
severe congenital cardiac defects such as HLHS. Current invasive approaches have had success 
in creating new pathways and modifying disease severity but are associated with a high risk of 
fetal demise [24, 42, 43]. 
  
1.4  Outline of this Dissertation 
This dissertation is organized in seven chapters to establish and improve the safety and 
efficacy of histotripsy for pediatric cardiac applications. 
Chapter 1 introduces histotripsy and its potential to become a transformative treatment 
option for a broad range of cardiac disorders. Specifically, it establishes the objective of this 
dissertation, to develop an ultrasound image guided histotripsy system optimized for safe and 
effective neonatal cardiac intervention in patients with HLHS. 
Chapter 2 investigates the potential of histotripsy to generate targeted intra-cardiac 
communications when positioned outside the body in an intact neonatal animal model to 
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establish the feasibility of this technique to create similar lesions in human neonates with 
congenital heart disease. 
Chapter 3 expands on this to determine the intermediate-term clinical, pathologic, and 
systemic effects of these intra-cardiac communications created by histotripsy in an intact 
neonatal animal model in an effort to address the safety profile of this technique as we continue 
to advance histotripsy toward clinical application for congenital heart disease. 
Chapter 4 presents a histotripsy-based cardiac therapy system integrated with real-time 
1D motion correction and treatment monitoring using ultrasound imaging. This motion 
correction is developed specifically for the high-speed motions present in a beating heart. The 
performance of the motion correction is quantified in vitro and a validated in a single in vivo 
experiment. 
Chapter 5 investigates potential therapy progress feedback metrics gathered from 
precisely timed color Doppler velocity measurements of the focal region immediately following 
histotripsy pulses. The correlation to the fractionation progress is established in vitro using tissue 
mimicking phantoms and ex vivo porcine liver tissue. 
Chapter 6 details the development of a histotripsy therapy transducer optimized for the 
pediatric cardiac application. The integration of this transducer into a complete ultrasound 
guided histotripsy therapy system is then detailed and a finished, functional prototype is 
presented. 
Chapter 7 summarizes the findings and contributions of this dissertation, and discusses 
the future work necessary to transition the project into the first clinical trial for non-invasive 
ASD creation in neonatal patients with congenital heart disease. 
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Chapter 2 
Therapeutic Ultrasound to Non-Invasively Create Intra-Cardiac 
Communications in an Intact Animal Model 
A majority component of this chapter has been published in Catheterization and Cardiovascular 
Interventions © 2011 Wiley. Reprinted, with permission, from [1]. 
 
2.1 Introduction 
Several forms of congenital heart disease benefit from the creation or enlargement of an 
intra-cardiac communication such as an atrial septal defect (ASD) to ensure appropriate delivery 
of oxygenated blood to essential organs [2-13].  ASDs and less commonly ventricular septal 
defects (VSDs) are typically created in the fetus or neonate using cardiac catheterization or 
surgery with the associated risks of thrombo-embolic complications, cardiac perforation, and 
occasionally death.   Previous work has demonstrated that histotripsy can create clearly 
demarcated perforations in excised porcine atrial and ventricular tissues using appropriate 
acoustic parameters [14].  In an open-chest canine model, histotripsy using an epicardial 
transducer position, accurately and efficiently generated ASDs without significant collateral 
damage or systemic clinical side effects [15]. 
The objective of this study was to determine if histotripsy could generate targeted intra-
cardiac communications when positioned outside the body in an intact neonatal animal model.  
Safe creation of a targeted lesion in this manner, through multiple tissues layers including bone 
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that may interfere with ultrasound propagation, should address the feasibility of this technique to 
create similar lesions in human neonates with congenital heart disease.  Because vertical 
orientation of the heart in pigs limits ultrasound access to the atrial septum, the interventricular 
septum was targeted in this study. 
 
2.2 Methods 
The procedures described here have been reviewed and approved by the University 
Committee on Use and Care of Animals at the University of Michigan. Nine healthy neonatal (2-
3 weeks) pigs weighing 3-5kg comparable, in size to the human neonate or infant, underwent 
percutaneous transthoracic histotripsy of the antero-apical muscular interventricular septum to 
avoid the conduction system. 
The animals were pre-anesthetized with Telazol (6mg/kg, IM) and Xylazine (2.2mg/kg 
IM), intubated and maintained on Isoflurane (1-3%) inhalation anesthesia, and paralyzed with 
pancuronium (0.1mg/kg) for the duration of the procedure. Heparin (200units/kg) was 
administered prior to the procedure and every hour thereafter if necessary.  During the histotripsy 
procedure, the pig was submerged neck deep in a semi-upright position (Figure 2-1a) in degassed 
water, which ensures ultrasound propagation into the animal without forming cavitation in the 
propagation pathway.   Each animal was monitored with pulse oximetry. 
 
2.2.1 Histotripsy Apparatus 
Ultrasound pulses for histotripsy treatment were generated by an external high power 
ultrasound therapy transducer. The transducer was placed in a degassed water filled cylinder 
covered by a thin plastic membrane that was acoustically transparent.  The cylinder was then 
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placed into the warm degassed water bath that contained the submerged pig.  This ensured 
continued ultrasound coupling from transducer, to water, through plastic membrane, to water and 
then to the chest wall (Figure 2-1a).  An 8MHz imaging transducer (S8, SONOS 7500, Philips 
Healthcare, Andover, MA) was placed through the center hole of the therapy transducer (Figure 
2-1b) and coupled to the neonatal pig in the same manner.   
The therapy transducer was designed in our laboratory and fabricated by Imasonic, S.A., 
Besançon, France. The circular transducer has a center frequency of 1 MHz, a geometric focal 
length of 90 mm, an outer diameter of 100 mm, and a 40 mm inner hole for housing an 
ultrasound imaging probe (Figure 2-1b). Ultrasound pressure waveforms of this therapy 
transducer were previously measured in degassed water using a fiber optic probe hydrophone 
[16]. The peak negative and positive pressures used in the following experiment were 16 MPa 
and 32 MPa, respectively. Taking into account the attenuation caused by the approximately 1.5 
cm thick chest wall tissue in the pathway, the peak negative pressure reaching the ventricular 
septum was estimated to be 13 MPa, resulting in a mechanical index of 13 [17].   The ultrasound 
pulses were 5 µs in duration (5 cycles at 1MHz) and separated by 1 ms (i.e., pulse repetition 
frequency = 1 kHz). 
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Figure 2-1: Histotripsy setup.  a) The neonatal pig is placed in a water bath.  The therapy and 
imaging transducers are placed into a cylinder filled with degassed water and coupled to the 
pig’s chest by a plastic membrane filled with water.  b) Close-up view of 1MHz therapy 
transducer with an imaging transducer protruding through center opening.  
2.2.2 Histotripsy Treatment 
Prior to the procedure, histotripsy pulses were applied to a water bath, producing a bright 
(hyperechoic) zone on a 2-dimensional ultrasound image. The front center of the hyperechoic 
zone was marked as the focal position (Figure 2-2a). The bubble cloud generated in the water for 
identifying focal location is larger than that in the tissue or blood. During the treatment, the 
bubble zone visualized by ultrasound was measured to be approximately 2-4 mm wide.  
An 8 or 12 MHz phased array imaging probe was used on the chest wall to identify a 
window which provided imaging of the anterior ventricular septum in the axial resolution 
without substantial overlying lung.  The therapeutic transducer was then moved by a 3-axis 
positioning system (Parker Hannifin, Rohnert Park, CA, USA) to align the focus marker on the 
ventricular septum (Figure 2-2b). The entire histotripsy procedure was guided by ultrasound 
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imaging using an 8 MHz phased array probe inserted into the central hole of the therapy 
transducer.   
To verify the targeting accuracy, a small number of pulses were applied to produce a 
bubble cloud on the RV portion on the muscular interventricular septum, usually anterior to the 
moderator band (Figure 2-2c). Once the targeting was accomplished, respirations were held (in 1 
minute intervals) and histotripsy treatment was applied to the ventricular septum. Ultrasound 
exposures were delivered in 1 minute intervals or until a hypoechoic (dark) channel was 
visualized through the ventricular septum.  The area was interrogated with color Doppler to 
confirm the creation of a VSD. 
 
Figure 2-2: Generation of a cavitation bubble cloud.  a) Prior to treatment, a cavitation bubble 
cloud is formed in degassed water to mark the focal point, seen by inserted arrow. b) The marked 
point is then positioned over the interventricular septum (IVS). c) Histotripsy is started and a 
hyperechoic bubble cloud is formed on the right ventricular (RV) side of the ventricular septum. 
LV (left ventricle) 
2.2.3 Post-treatment Process 
Within 2 hours after VSD creation, 6 of 9 animals were euthanized with a lethal dose of 
Pentobarbitol IV (100 mg/kg). In 3 animals, euthanasia was deferred for 2-3 days to evaluate 
sub-acute cellular changes related to histotripsy therapy and VSD creation.  After euthanasia, the 
heart and lungs were extracted and fixed in a 10% formalin solution and dissected after a week 
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of fixation. The organs were first examined by gross evaluation and then processed with standard 
hematoxylin and eosin (H&E), phosphotungstic acid-hematoxylin (PTAH), and Gomori staining 
for pathological evaluation.  
 
2.3 Results 
Histotripsy applied extracorporeally propagated through multiple tissues layers including 
skin, bone, and portions of lung, and created a VSD in all 9 animals within 20 seconds to 4 
minutes of therapy (Table 2-1).  
Table 2-1: Summary of Histotripsy Treatments and Results 
Case Tx time 
(min) 
Echo VSD 
size center 
(mm) 
Path VSD 
size center 
(mm) 
Flanking 
injury RV 
side (mm) 
Flanking 
injury LV 
side (mm) 
Complications 
 Immediate euthanasia 
1 1.3 2.5 4 3.2 3.4 None 
2 0.5 2.5 2.7 4.1 2.8 None 
3 4 2 3.5 4.4 3.8 Bradycardia*
4 1.8 3.3 2.7 3.7 2.7 None 
5 0.33 4.2 4.4 3.3 2.7 Bradycardia*
6 3 6.5 5.2 1.2 1.1 None 
Mean 1.8 3.5 3.7 3.3 2.8  
STD 1.4 1.7 0.7 1.1 0.9  
 Delayed euthanasia 
7 1.6 3.3 2.8 0.6 0.9 None 
8 1.7 4 NA 1.9 1.1 None 
9 2.4 2 3.1 1.3 1.6 None 
Mean 1.9 3.1 3.0 1.3† 1.2†  
STD 1.2 1.4 1.3 1.4 1.1  
Echo VSD size center column represents measurements of the center of VSD from two-
dimensional imaging.  Path VSD size center is a measurement of the VSD on H&E slides 
measured at the center of the defect.  Measurement for animal 8 is not available (NA) secondary 
to tissue processing.  Flanking injury RV (right ventricle) and LV (left ventricle) side are 
measurements from H&E slides of flanking injury from the border of acellular debris/VSD to the 
outermost border of myocyte damage taken from both sides of the created defect at the RV and 
LV surfaces respectively, and then averaged. STD (standard deviation) Tx (therapy). 
* both animals recovered after a single dose of epinephrine 
† p < 0.05 by 2 tailed T-test when compared to immediate euthanasia group 
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VSD creation was confirmed with 2-dimensional imaging, color flow Doppler (Figure 
2-3), and pathologic evaluation.   
 
Figure 2-3: Creation of VSDs by histotripsy.  a) Image of the ventricular septum in long axis 
prior to treatment.  b)  After treatment a VSD is seen on 2 dimensional ultrasound imaging, and 
(c) shunting is seen across the ventricular septum with color flow Doppler.  Another example of 
a created VSD is seen in short axis with images prior to treatment (a), post treatment (b) and with 
color flow Doppler (c). 
The size of created VSDs was variable (2-6.5 mm).  All animals tolerated the procedure.  Minor 
complications including transient hypoxia and ventricular ectopy were self-limited to the time 
during treatment.  Seven animals received no intervention while 2 animals required epinephrine 
therapy for bradycardia.   There were no major acute complications defined as pericardial 
effusion, sustained arrhythmia, or death.  Two animals had mild unintended damage to the RV 
free wall due to its close proximity to the therapeutic focus.  In the 3 animals, where euthanasia 
was deferred for 2-3 days post VSD creation, no changes in behavior, gait, appetite, vital signs, 
or other general characteristics were observed suggesting no global or neurologic effects from 
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histotripsy treatment.  VSD size also remained the same in these animals, although a surrounding 
rim of increased echogenicity was apparent, likely resulting from inflammation and/or edema 
(Figure 2-4). 
 
Figure 2-4: VSD two days after histotripsy therapy.  a-b) Parasternal long axis view of VSD two 
days after creation in 2D and with color flow Doppler.  c) 3-dimensional representation of same 
VSD shown in a modified apical four chamber view showing persistence of the septal defect.  
Note the hyperechoic (bright) rim surrounding the defect marked by white arrows. 
Evaluation of function prior to histotripsy therapy and immediately before euthanasia 
(either acute or after 2-3 days) revealed no overt differences in global ventricular contractility, 
although regional wall motion abnormalities could not be thoroughly evaluated in this acute 
study.  Two dimensional and color flow Doppler analysis of the heart after treatment revealed no 
significant changes in valve function post procedure. 
 
2.3.1 Gross Morphology 
In all 9 neonatal pigs studied, the epicardial surfaces appeared intact (Figure 2-5a-c). 
Seven animals had intact endocardial surfaces except for the created VSDs. In 2 animals where 
the bubble cloud did appear very close to the right ventricular anterior free wall, minor 
discoloration of the endocardial surface was visualized.  No other unintended damage was 
visualized on gross examination.  
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Cardiac dissection of the 6 animals euthanized immediately post-procedure revealed 
demarcated damage in the ventricular septum.  The VSD and surrounding hemorrhage indicated 
by dark colorization was observed on both sides of ventricular septum (Figure 2-5d).  In the 3 
animals with delayed euthanasia, the lumen of the VSD was more demarcated with smooth walls 
and the flanking hemorrhage appeared less substantial (Figure 2-5e). 
 
Figure 2-5: Cardiac pathology after histotripsy treatment.  Gross pathology of the heart revealed 
no damage to the epicardial surface on the anterior (a), basilar (b), or posterior regions (c).  
Dissection revealed demarcated damage across with ventricular septum with flanking zones of 
hemorrhage in immediately euthanized animals (d).  e)  Similar lesions were observed in animals 
with delayed euthanasia but with smoother borders and less apparent flanking hemorrhage and/or 
damage. 
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Gross evaluation of the lungs revealed normal appearing lungs in 5 animals and very mild 
areas of congestion and focal hemorrhage in 4 comprising < 5% of lung tissue.  No evidence of 
pulmonary embolus was found in the lungs on gross pathology in either the acute or sub-acute 
setting (Figure 2-6a). The ribs and overlying tissue in the ultrasound pathway were also 
examined.  No visible damage was observed. 
 
Figure 2-6: Lung pathology.  a) Gross evaluation of the lungs revealed mostly healthy appearing 
tissue with only focal areas of hemorrhage or congestion (arrow).  On histological analysis (b) no 
microscopic evidence of thrombo-embolic events were visualized. 
2.3.2 Pathology 
On H&E stained slides from animals immediately sacrificed, the central damage zone of 
the VSD contained acellular debris and platelet/fibrin deposits (Figure 2-7a-b).  The average 
zone of necrosis in the center of the VSD was measured to be 3.7±0.7 mm (Table 2-1).  VSDs 
from animals with delayed euthanasia had substantially less acellular debris (Figure 2-7c) but 
were similar in size with a mean of 3.0±1.3 mm (Table 2-1). 
Immediately outside the acellular zone in acutely euthanized animals was a rim of 
hemorrhage and structurally intact myocytes with a more eosinophilic hue and contracted nuclei 
 23 
 
in comparison to normal myocytes (Figure 2-7b). These myocytes were likely affected by 
histotripsy. The width of hemorrhage (measured from the acellular zone border to distal portion 
of flanking injury on both sides of defect in multiple tissue slices and then averaged to provide a 
circumferential report of flanking injury) on the right ventricular side was 3.3±1.1 mm and on 
the left ventricular side 2.8±0.9 mm (Table 2-1).   Beyond this rim of damaged cells were normal 
appearing myocytes with no further discernable damage (Figure 2-7b).  In the animals allowed to 
survive 2-3 days, evaluation of the lesion revealed a clear lumen compared to the acutely 
sacrificed animals and the flanking region contained activated fibroblasts and occasional 
inflammatory cell invasion suggesting progression of an inflammatory remodeling process 
(Figure 2-7c-d).  The extent of flanking injury and/or inflammation was significantly less (1.3 
mm vs. 3.3 mm on RV side and 1.2 mm vs. 2.8 mm on the LV side) comparing animals with 
delayed euthanasia to those with acute sacrifice (Table 2-1). 
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Figure 2-7: Histology of ventricular septum.  a) Histological analysis revealed a central area of 
acellular debris and necrosis and flanking areas of contraction necrosis with hemorrhage in 
immediately sacrificed animals. (b) High power imaging of this border reveals tight demarcation 
of necrosis and myocyte injury (solid arrow) with normal appearing myocytes in the top left of 
image (dashed arrow).  c)  In animals with delayed euthanasia, the VSD is more clearly 
demarcated without acellular debris and d) there is evidence of cellular remodeling with presence 
of activated fibroblasts (arrows). 
The areas of discoloration found in the right ventricular free wall in 2 animals described 
above corresponded to minor areas of contraction necrosis and hemorrhage suggesting the tissue 
was mildly affected by the histotripsy therapy.  There were no areas of acellular debris or 
platelet/fibrin deposits.  No other damage was noted in the heart on histological evaluation. 
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Histological evaluation of the lung revealed mostly normal appearing lung tissue with 
focal areas of congestion and hemorrhage (Figure 2-6b).  There was no evidence for thrombo-
embolic events and no debris from tissue fractionation was seen as evaluated by Gomori 
trichrome and PTAH staining. 
 
2.4 Discussion 
Therapeutic creation of cardiac septal defects in necessary for the palliation of several 
forms of congenital heart disease [2-5, 7, 9-11, 13] and is typically performed invasively with 
surgical or cardiac catheterization techniques [3, 7, 8].   This study demonstrates feasibility of 
“non-invasive” creation of an intra-cardiac defect by percutaneous pulsed cavitational ultrasound 
or histotripsy.  Nine VSDs were created in 9 intact neonatal pigs with minimal collateral damage 
or systemic side-effects.  
The size of created VSDs was variable (2-6.5 mm),  likely related to varying aberration 
of ultrasound energy from intervening bones and tissue, as well as motion and consistency of the 
targeted ventricular septum.  However, no correlations could be definitively made between 
amount of overlying tissue (range 14-17 mm) or septal motion (range 2.6-5 mm) on VSD size.    
Flanking injury, comparable to that seen in ASD creation in the open-chest canine model [15], 
was also observed and likely related to some of the same factors.  These variables should be de-
emphasized with an unobstructed acoustic window, such as the subcostal approach in human 
neonates (or other non-human primates), targeting of the thinner and less mobile atrial septum, as 
well as with improved transducer design allowing for motion tracking, ECG gating, and 
improved targeting (by decreasing focal distance and improving imaging resolution).   
 26 
 
The pathologic evaluation of the animals allowed to survive 2-3 days after treatment 
revealed persistence in the size of VSD and less flanking injury with evidence of cellular 
remodeling (activated fibroblasts and inflammatory cell invasion), suggesting that some of the 
early flanking injury may be salvageable if not reversible.  Further delineation of this 
inflammatory response, lesion maturation, and any systemic complications is currently under 
investigation in long-term studies.   
No thrombo-embolic events were observed, consistent with prior demonstrations that 
particles created by histotripsy are largely < 6 µm (the size of a red blood cell) [18], a size 
unlikely to cause harm [19].  Still, more robust evaluation of end-organ complications such as 
thrombo-embolic events are currently being investigated by utilizing transcranial Doppler during 
treatment and diffusion MRI to evaluate brain and other end-organs after therapy.  Preliminary 
MRI data have revealed no evidence of cerebral lesions up to 1 month after defect creation. 
 
2.5 Conclusion 
These data in combination with previous data demonstrating effective creation of ASDs 
in an open-chest dog model suggest that “non-invasive” creation of both atrial and ventricular 
septal defects via histotripsy is potentially feasible in the human neonate.  Further investigation 
into potential side effects (embolic risk, maturation of lesions, and longer follow-up), improved 
transducer focusing and size optimization, and refinement of the approach are underway and 
necessary to develop the clinical potential of histotripsy for congenital heart disease and other 
applications.  
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Chapter 3 
Intermediate-term Effects of Intra-cardiac Communications Created Non-
invasively by Therapeutic Ultrasound (Histotripsy) in a Porcine Model 
A majority component of this chapter has been published in Pediatric Cardiology © 2011 
Springer. Reprinted, with permission, from [1]. 
 
3.1 Introduction 
 Clearly demarcated perforations have been created previously by histotripsy in excised 
porcine cardiac tissue [2]. In addition, histotripsy has created atrial septal defects (ASDs) in an 
open-chest canine model [3] and was able to create ventricular septal defects (VSDs) through the 
intact chest of a neonatal pig without significant acute complications. These findings suggest that 
histotripsy has the potential to become a novel, noninvasive clinical tool not only for intracardiac 
communication creation but also for other applications involving tissue removal or destruction. 
 This study aimed to determine the intermediate-term clinical, pathologic, and systemic 
effects of intracardiac communications created by histotripsy in an intact neonatal animal model 
in an effort to address the safety profile of this technique as we continue to advance histotripsy 
toward clinical application for congenital heart disease. VSDs were targeted in this study as well 
because of the poor acoustic window to the atrial septum in neonatal pigs secondary to a 
different heart/lung orientation in the chest compared with humans. 
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3.2 Materials and Methods 
The procedures described in this report have been reviewed and approved by the 
University Committee on Use and Care of Animals at the University of Michigan. For this study, 
six pigs weighing 3–5 kg underwent histotripsy-mediated VSD creation and were allowed to 
survive 1 month to provide intermediate-term data on lesion maturation and systemic effects. 
They then were compared with nine pigs that previously had undergone histotripsy-mediated 
VSD creation [4]. Thus, 15 pigs were evaluated in this study. 
A detailed description of the VSD creation procedure has been reported previously [4]. 
We created VSDs because of the poor acoustic window to the atrial septum in this neonatal 
model. Briefly, the animals were preanesthetized with intramuscular Telazol (6 mg/kg) and 
xylazine (2.2 mg/kg), intubated, maintained on isoflurane (1–3%) inhalation anesthesia, and 
paralyzed with pancuronium (0.1 mg/kg). Heparin (200 U/kg) was administered before the 
procedure and every hour thereafter if necessary. During the histotripsy procedure, the pig was 
submerged neck deep in a semi-upright position in degassed water, which allowed ultrasound 
coupling and ensured propagation into the animal. Each animal was monitored with pulse 
oximetry and ultrasound imaging. 
 
3.2.1 Histotripsy Therapy  
The therapy transducer was designed in our laboratory and fabricated by Imasonic, S.A. 
(Besançon, France). The circular transducer has a center frequency of 1 MHz, a geometric focal 
length of 90 mm, an outer diameter of 100 mm, and a 40-mm inner hole to house an ultrasound 
imaging probe (S8, SONOS 7500; Philips Healthcare, Andover, MA, USA) for real-time 
monitoring during therapy. The ultrasound pressure waveforms of this therapy transducer were 
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measured previously in degassed water using a fiberoptic probe hydrophone [5]. The following 
experiment used a peak negative pressure of 16 MPa and a positive pressure of 32 MPa. Taking 
into account the attenuation caused by the approximately 1.5 cm-thick chest wall tissue in the 
pathway, the peak negative pressure reaching the ventricular septum was estimated to be 13 MPa 
[6]. This resulted in a mechanical index (MI) of 13, significantly higher than the maximum MI 
for diagnostic ultrasound of 1.9 [7]. The ultrasound pulses were 5 µs in duration (5 cycles of 1 
MHz each) and separated by 1 ms (i.e., a pulse repetition frequency of 1 kHz). Before therapy, 
histotripsy pulses were applied to a water bath, producing a bright (hyperechoic) zone on a two-
dimensional ultrasound image from the imaging transducer in-line with therapy. The front center 
of the hyperechoic zone was marked as the focal position. The therapeutic and in-line imaging 
transducers then were moved by a three-axis positioning system (Parker Hannifin, Rohnert Park, 
CA, USA) to align the focus on the ventricular septum. The best acoustic window, minimizing 
lung and bone obstruction, in the right parasternal position was chosen. 
Once the ultrasound transducers were in position, a small number of pulses were applied 
to produce a bubble cloud (approximately 2–4 mm wide) on the right ventricular side of the 
muscular interventricular septum, usually anterior to the moderator band, to confirm targeting 
accuracy. Respirations then were held (in 1-min intervals), and histotripsy treatment was applied 
to the ventricular septum. Ultrasound exposures were delivered until a hypoechoic (dark) 
channel was visualized through the ventricular septum. The area was interrogated with color 
Doppler to confirm the creation of a VSD. 
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3.2.2 Post-treatment Process  
As described previously [4], six animals (acute) were killed with a lethal dose of 
pentobarbitol (100 mg/kg) administered intravenously within 2 h of VSD creation, and three 
animals (subacute) were killed 2 to 3 days after VSD creation for evaluation of subacute cellular 
changes. The six animals from this study were killed 1 month (intermediate term) after VSD 
creation and monitored clinically during this time. 
After the animals were killed, the heart and lungs were extracted, fixed in a 10% formalin 
solution, and dissected after a week of fixation. The organs were first examined by gross 
evaluation and then processed with standard hematoxylin and eosin (H&E) staining for 
pathologic evaluation. 
The six intermediate-term animals had echocardiograms at the time they were killed for 
evaluation of ventricular function. They also were evaluated by magnetic resonance imaging 
(MRI) for any cerebral ischemic events. The MRI was performed at least 2 weeks after VSD 
creation on a 2T Varian Unity/Inova (Agilent, Santa Clara, CA) small animal imaging system. 
The piglets were placed in a specially built animal holding device, and the brain was imaged 
with the aid of a home-built radiofrequency probe. Multislice, spin-echo imaging (repetition time 
[TR] = 3 s, echo time [TE] = 60 ms) was performed using a slice thickness of 3 mm and an in-
plane resolution of 600 lm. Images were acquired with and without diffusion-encoding gradients 
(b = 420 s/mm2) to identify possible regions of ischemia. 
 
3.3 Results 
Histotripsy therapy propagated through multiple tissue layers including skin, bone, and 
portions of lung and created a VSD in 15 animals during 20 s to 13 min of therapy (mean, 3.1 ± 
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3.2 min). All the animals survived until scheduled to be killed. Minor complications including 
transient hypoxia and ventricular ectopy were self-limited to the time during treatment. There 
were no persistent arrhythmias or pericardial effusions. The VSDs, confirmed by color-flow 
Doppler (Figure 3-1), ranged in size from 2 to 6.5 mm (mean, 3.7 ± 1.6 mm). All VSDs persisted 
until the scheduled killing of the animals except for two initially small VSDs (2 and 2.5 mm) in 
the intermediate-term group, which spontaneously closed by 1 month. The remaining four VSDs 
in the intermediate-term group increased by an average of 1.0 ± 0.7 mm by the age of 1 month 
(Figure 3-1). 
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Figure 3-1: Color-flow Doppler echocardiogram images of VSDs created by histotripsy in 
animals allowed to survive for 1 month. Small lesions (a, b) spontaneously closed by 1 month, 
whereas larger initial lesions (c–f) had expanded by an average of 1 mm by the time the animals 
were killed. 
Intermediate-term animals surviving 1 month experienced normal weight gain (Figure 
3-2) and displayed no clinical evidence of untoward effects. Two animals in this group did have 
asymptomatic ascites seen on necropsy. These animals had the largest VSDs, suggesting a 
component of heart failure associated with the septal defect. The animal husbandry staff 
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observed no change in gait, activity, or affect. Echocardiograms performed before VSD creation 
and at the killing of the intermediate-term animals showed no global change in ventricular 
systolic function, as determined by two blinded interpreters. 
 
Figure 3-2: All the animals gained weight appropriately during the 1-month follow-up period. 
3.3.1 Gross Morphology  
No damage to intervening tissues was observed in any of the 15 neonatal pigs studied, 
and the epicardial surfaces appeared to be intact. In 13 of the animals, the endocardial surfaces 
were intact except for the created VSDs. Only 2 of the animals had minor discoloration of the 
endocardial surface of the right ventricular free wall. In these cases, the bubble cloud was in 
close proximity to this surface. No other unintended damage was visualized at gross examination. 
Cardiac dissection showed demarcated damage in the ventricular septum of all the 
animals. In the acute animals (killed within 2 h), the VSD was filled with homogenized debris 
and flanked by hemorrhage and dark discoloration (Figure 3-3a, b). In 2 to 3 days (subacute), the 
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lumen of the VSD was clear, with improvement of the flanking hemorrhage and discoloration 
(Figure 3-3c, d). After 1 month of survival (intermediate term), no flanking injury or 
inflammation was observed, and the VSD was clearly demarcated with smooth borders (Figure 
3-3e, f). In the two animals that had spontaneous VSD closure, fibrotic tissue was visualized at 
the previous defect without surrounding injury. 
 
Figure 3-3: (a, b) Gross morphology of VSDs created by histotripsy therapy in animals killed 
acutely shows that the septal lesion was full of acellular fractionated debris and surrounded by 
hemorrhage. (c, d) By 3 days, flanking hemorrhage has improved, and the VSD lumen is clear 
without debris. (e, f) After 1 month, the myocardium appears to be healed, and a demarcated 
VSD is seen without evidence of surrounding hemorrhage or injury. 
For four of the six acute animals, gross evaluation of the lungs showed very mild areas of 
congestion and focal hemorrhage comprising less than 5% of lung tissue. No evidence of 
hemorrhage or lung injury was observed by the pathologist (D.G) in the subacute or 
intermediate-term animals, and no evidence of pulmonary embolic events was observed in any 
animal of this series. 
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3.3.2 Pathology  
In the acutely killed animals, histologic analysis showed VSDs consumed with acellular 
debris and platelet/fibrin deposits, with flanking hemorrhage and myocyte injury spanning 
approximately 3 mm from the VSD border (Figure 3-4a). In the subacute animals, the lumen of 
the VSD was clear, and the extent of flanking injury was less (1.3 mm), with infiltration of 
inflammatory/remodeling cells such as fibroblasts and macrophages (Figure 3-4b). By 1 month 
(intermediate term), the VSD was completely endothelized and surrounded by fibroblastic scar 
tissue immediately adjacent to the defect and then flanked by normal myocardium (Figure 3-4c). 
 
Figure 3-4: Histology of histotripsy-created VSDs. (a) Acutely, the VSD proper is consumed 
with acellular fractionated fibrin debris (star) flanked by hemorrhage and myocyte injury. (b) By 
3 days, the VSD proper is clear, and cellular remodeling has begun with infiltration of fibroblasts 
(arrow) and an improvement in flanking hemorrhage. (c) After 1 month, an endothelial border 
exists surrounded by fibroblastic scar tissue immediately adjacent to normal-appearing 
myocardium. 
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3.3.3 Brain Imaging 
All the intermediate-term animals underwent MRI of the brain a minimum of 2 weeks 
after VSD creation to evaluate for potential systemic embolic events. Diffusion weighted MRI 
showed no ischemic lesions. 
 
3.4 Discussion 
The ability to augment the structure or communications in the heart of an infant born with 
congenital heart disease, avoiding open heart surgery or invasive cardiac catheterization, could 
significantly advance the field of pediatric cardiology. Several congenital heart lesions require 
therapeutic creation of septal defects [8-13], which currently requires invasive procedures, thus 
identifying a clinical application for noninvasive ultrasound therapy. This study demonstrates the 
intermediate-term safety and effects of pulsed cavitational ultrasound (histotripsy) for the 
creation of intracardiac communications, building on previous reports of this technology. 
A total of 15 VSDs (9 created previously and 6 created in this intermediate-term study) 
were created noninvasively using histotripsy therapy. All the animals survived the procedure, 
and the six animals killed after 1 month had no clinical symptoms and gained weight 
appropriately. In addition, ventricular systolic function was preserved, and no evidence of 
thromboembolic events was observed based on lung pathology and MRI of the brain. The lack of 
embolic events is consistent with in vitro data, showing that most particles created by histotripsy-
induced tissue fractionation are less than 6 μm in size (size of a red blood cell) [14]. In all, 
although more robust evaluation of other distal tissues is necessary before clinical advancement, 
the aforementioned data suggest that histotripsy cardiac therapy is safe and that effects are 
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limited to the targeted region, similar to other reports of this technology used in different regions 
of the body [15-18]. 
Flanking hemorrhage and myocyte injury observed in the animals killed immediately 
after the procedure were completely resolved by 1 month, with some lesion expansion but 
suggesting that the unintentional damage was recoverable. However, in attempts to manipulate 
cardiac tissue, the smallest amount of acute unintentional damage, such as the mild right 
ventricular free wall damage seen in two acute animals, could be devastating. This damage likely 
resulted from the close proximity of the free wall to the target, the bubble cloud size, and motion. 
Thus, similar to attempts using other forms of therapeutic ultrasound [19-21], innovative efforts 
to incorporate ultrafast motion tracking, to decrease aberration from intervening tissues (i.e., 
bones), and to synchronize real-time color-Doppler feedback are underway to increase therapy 
accuracy further and decrease unintended injury. 
The design of new therapeutic transducers with optimized focal distances allowing 
improved imaging quality represents another essential advancement necessary before clinical 
application. Acoustic coupling also requires improvement to prevent the need for water 
submersion used in these studies. Once these hurdles are surpassed and new optimized 
transducers with localized coupling ability are designed and tested, device exemption from the 
Food and Drug Administration will be obtained, paving the way for an inaugural clinical trial of 
histotripsy for congenital heart disease. Notably, transducer design for neonatal ASD creation 
can be simplified because of the optimal subcostal acoustic window free of intervening bone and 
the limited motion of the atrial septum in neonates [3], allowing earlier entry of histotripsy into 
the clinical realm. 
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Although others have used the thermal effects of high-intensity ultrasound for cardiac 
applications such as ablation of atrial fibrillation or other arrhythmias [22-24], no transcutaneous 
noninvasive ultrasound technique with the ability to create targeted cardiac perforations without 
acute or long-term sequelae has been reported. With further refinement and development, it is 
hoped that histotripsy may become an innovative clinical tool not only for noninvasive ASD 
creation but also for other lesions such as hypertrophic cardiomyopathy with obstruction, 
subaortic stenosis, membranous pulmonary atresia, and arrhythmias in which targeted tissue 
removal or destruction is required and may benefit from a noninvasive ultrasound approach. 
Furthermore, histotripsy also has been used noninvasively to create cardiac lesions in a fetal 
sheep model [11], suggesting that with further refinement and safety evaluation, histotripsy could 
play an exciting role in fetal cardiac intervention, further expanding its potential clinical 
applications. 
 
3.5 Conclusion 
Transcutaneous histotripsy is a safe and effective technique to create intra-cardiac 
communications non-invasively, without intermediate-term untoward effects.  With further 
refinement and development, histotripsy has the potential to become an effective tool for 
palliation of congenital heart disease. 
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Chapter 4 
Histotripsy Cardiac Therapy System Integrated with Real-time Motion 
Correction 
A majority component of this chapter has been published in Ultrasound in Medicine & Biology 
© 2013 Elsevier. Reprinted, with permission, from [1]. 
 
4.1 Introduction 
Histotripsy has been successful in creating intra-cardiac communication in an open chest 
canine heart model [2], an intact neonatal porcine model [3, 4], and an intact in utero fetal sheep 
model [5]. The perforations created in these studies generally have 1-4 mm of hemorrhage 
surrounding the perforation. During these experiments, the heart motion perpendicular to the 
direction of ultrasound therapy propagation was small (< 2mm), while the heart motion along the 
direction of therapy propagation was sufficiently large (up to 17 mm) to move the septum out of 
the focal zone, resulting in reduced treatment efficiency and the potential for collateral damage. 
Furthermore, in cardiac applications involving adult hearts, such as atrial fibrillation, the cardiac 
motion will likely be significantly larger in both perpendicular and parallel directions to the 
ultrasound propagation.  As such, the improved accuracy and efficiency motion correction 
provides will be increasingly necessary in order to reliably administer histotripsy therapy in these 
future applications. 
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Several target motion estimation and correction algorithms have been explored in 
conjunction with high intensity focused ultrasound (HIFU) therapy. Respiratory gating has been 
used to synchronize with HIFU applications to switch off therapy during breaths [6, 7]. More 
sophisticated approaches have also been developed to adjust the therapy focus to follow the 
target position in real-time. For example, ultrasound speckle tracking was employed to adjust the 
therapy focus to track the respiration motion using correlations of pulse-echo sequences from a 
subset of the transducers of the therapy phased array [8, 9]. Optical flow image processing 
techniques have also been utilized on real-time 2D ultrasound images for motion compensation 
in HIFU application [10]. Motion compensation was also investigated for magnetic resonance 
imaging (MRI) guided HIFU, such as the use of periodic respiratory motion and statistical 
models [11-14] and tracking the target position in the image plane while compensating for the 
out-of-plane motion by dynamic slice tracking [15]. These motion correction methods showed 
improvement in treatment efficiency and collateral damage reduction, but were mostly focused 
on treating slower moving abdominal organs.  
The addition of fast cardiac motion on top of large respiratory motions significantly 
increases the complexity of tracking targets in the heart as opposed to tracking in other organs. 
Many algorithms have been developed for tracking cardiac motion in ultrasound imaging to 
evaluate heart function. These methods include myocardial border segmentation using 
deformable models [16], myocardial motion and deformation estimation using phase shift 
estimation [17], spatio-temporal nonrigid registration with B-Spline interpolation [18], optical 
flow methods to compute local myocardial movements [19], and block motion estimation and 
speckle tracking techniques [20].  However, none have yet been combined to adjust the therapy 
focus in real-time for motion correction in an integrated ultrasound cardiac therapy system. 
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In this chapter, we present a histotripsy-based cardiac therapy system integrated with 
real-time motion correction and treatment monitoring using ultrasound imaging. For this system, 
the motion correction must run at high frame rates due to the fast heart motion, and be robust 
against direct and indirect acoustic and electromagnetic interference from the high intensity 
histotripsy pulses. To address these challenges, we developed an ultrasound image-based motion 
tracking algorithm that utilizes a fast block matching technique, with real-time filtering for 
estimation error reduction. This algorithm was chosen due to its low computational requirements 
and ease of integration with the ultrasound image-guided histotripsy therapy system. In addition 
to the motion tracking capability, this integrated system has ultrasound imaging as real-time 
treatment monitoring that is free from interference of the therapy pulses. This integrated system 
was tested by performing two dimensional (2D) motion tracking based on ultrasound images and 
applying the motion feedback to correct for the one dimensional (1D) motion along the therapy 
axis by steering the focus of the annular therapy array. In this initial study lateral motion 
correction was not performed based our previous experiments where communication through the 
atrial or ventricular septum (a membrane separating the two atria or ventricles) was generated for 
treatment of congenital heart diseases [2-4]. In those studies, the axial motion (along the 
direction of ultrasound propagation) was observed to be the main motion of the atrial/ventricular 
septum, with only small motion in other directions. Due to the limitations of the hardware, 2D 
instead of three dimensional (3D) motion tracking was tested for this initial feasibility study. The 
integrated system developed here could potentially be upgraded to 3D by replacing the annular 
therapy array with a 2D phased array and replacing the 2D imaging probe with a 3D imaging 
probe.  
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The performance of the current integrated system was evaluated in three steps in vitro 
followed by in vivo feasibility testing. First, to evaluate the tracking accuracy of the integrated 
system at different velocities, the actual movement path of the target was recorded by high speed 
optical images and compared with the estimated movement path from the algorithm. Second, to 
evaluate the treatment accuracy of the system, the size of the lesion created in moving tissue 
phantoms with the motion correction was compared to that produced without correction. Third, 
to investigate the efficiency of the system, the erosion rate produced with the motion correction 
in tissue phantoms and ex vivo porcine cardiac tissue was compared to that without correction. 
Finally, an in vivo feasibility experiment was conducted to determine the feasibility of 
integrating the algorithm into histotripsy therapy image guidance and targeting procedures. 
 
4.2 Methods 
4.2.1 Motion Tracking System Design 
The motion tracking system we developed uses a custom algorithm to track a feature on 
ultrasound images using image processing techniques. This algorithm was integrated directly 
into the imaging sequence of an ultrasound imaging system. The imaging acquisition was 
synchronized with a 1 MHz histotripsy therapy array to minimize the interference of the therapy 
pulses on the ultrasound image. The imaging system’s host computer processed the tracking 
algorithm and provided the results to the therapy array controller, updating the therapy focal 
position in real-time. Meanwhile, the treatment process was monitored through ultrasound 
imaging. The integrated system, consisting of the motion tracking algorithm, the ultrasound 
imaging system, and the histotripsy therapy system is described in detail below. 
Ultrasound Imaging System 
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The ultrasound images were acquired by a Verasonics® Data Acquisition System (VDAS; 
Verasonics Inc., Redmond, WA, USA), interfaced with a Mac Pro desktop computer (Apple Inc., 
Cupertino, CA, USA), using an ATL HDI P7-4 (Philips, Andover, MA, USA), 5 MHz phased 
array imaging probe. This system was chosen for its high frame rate capabilities (by using a 
variable number of plane wave acquisitions) and flexible programmability allowing integration 
of processing algorithms within the imaging sequence. 
To avoid interference from the histotripsy pulses, ultrasound image acquisitions were 
delayed 0.2 – 0.5 ms after the histotripsy pulses. Following this delay, image acquisition required 
135 µs per steered plane wave acquisition (round-trip propagation time, which is dependent on 
the depth of the target).  The number of plane wave acquisitions per image was chosen to balance 
sufficiently high image quality (spatial resolution) with a sufficiently high frame rate (temporal 
resolution). Though image quality could be improved by increasing the number of plane wave 
acquisitions per image, doing so reduced the overall frame rate. Therefore, while a single plane 
wave acquisition per image provided sufficient image quality and a higher average frame rate (62 
Hz) for motion tracking in vitro, 5 steered plane wave acquisitions were necessary for tracking in 
the in vivo experiment to achieve adequate imaging quality through the increased overlying 
tissue, reducing the average frame rate (31 Hz). Because of the low duty cycle (< 1%) used in 
histotripsy therapy pulses; the period between adjacent histotripsy pulses was sufficiently long to 
allow imaging acquisitions. Figure 4-1 shows a timing diagram example to illustrate the 
synchronization. 
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Figure 4-1: Timing diagram illustrating the synchronization and integration of the imaging 
sequence between therapy pulses with typical parameters. 
Motion Tracking Algorithm 
Our real-time motion-tracking algorithm is based on tracking a distinguishable target 
feature on ultrasound images by comparison with a reference sub-image containing that target 
feature (reference block). First, the location of a moving target is identified in the current 
ultrasound image frame by finding the best match of the reference block in the current ultrasound 
frame using a block matching method. A reference image of the target is captured before therapy, 
which contains unique features or borders that can be distinguished from other structures in its 
vicinity. This reference block can be located within the therapy target region or nearby, provided 
the target region and reference feature move in unison, allowing the flexibility to track a 
prominent tissue feature but treat in another nearby location. The best matching block in the 
current frame in comparison to the reference block is identified by minimization of the sum of 
absolute difference (SAD) criterion. The error for a given location is found by subtracting the 
reference image from a block of the current frame centered at this potential new target location, 
and the absolute values of these pixel errors were summed to obtain the SAD (Equation 4.1). 
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 Equation 4.1 
In this equation, the reference block “ݎ݂݁ሺ∙,∙ሻ” of size ሺ ௫ܰ, ௬ܰሻ is compared to the same-sized 
block surrounding the point ሺ݅, ݆ሻ in the current image frame “݅݉ܽ݃݁ሺ∙,∙ሻ”. 
To accelerate the computation, diamond search technique [21] was used to minimize 
search time in the current frame using knowledge of the target’s position in the previous frame. 
First, to establish the initial position estimate on the first ultrasound frame, a single coarse search 
is performed over the entire frame. In subsequent frames, the diamond search procedure starts at 
the estimate from the previous frame, computing the SAD error for this location and those in a 
large diamond search pattern (LDSP) around it (Figure 4-2). Re-centering at the location among 
these with the lowest error, it computes the necessary additional SAD values to cover another 
LDSP around this point.  This continues until the center point maintains the lowest SAD value, at 
which time a small diamond search pattern (SDSP) around that location produces the final 
estimate of the target position. This approach remains accurate so long as the overall frame rate 
is fast enough to keep the target’s frame to frame motion small, thus ensuring the local minimum 
SAD corresponds to the target’s new position. 
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Figure 4-2: Illustration of the diamond search procedure: starting from the previous target 
position (bold circle), successive LDSP iterations (1-3) are computed with the best match of each 
shaded gray. Once the center location remains the best match (shaded “2” remained best match 
on iteration 3), the SDSP locations (4) are tested and the best match is the new estimate of the 
target’s position (bold square). 
The block matching estimate is filtered from frame to frame using a Kalman filter to 
reduce the interference of the noise on tracking. A need for filtering was based on early testing of 
the algorithm using ultrasound B-mode videos taken during in vivo experiments of two neonatal 
pigs and two fetal sheep. Without the Kalman filter, the estimated position within ultrasound 
videos was observed to jump around the actual position of the target rapidly. The addition of the 
Kalman filter removed this rapid fluctuation and improved tracking accuracy by an estimated 
13%. Our implementation of the Kalman filter uses the horizontal and vertical positions (݄ሺ݊ሻ 
and ݒሺ݊ሻ) and velocities (݄′ሺ݊ሻ and ݒ′ሺ݊ሻ) as the current state, with the estimate of the current 
position equal to the previous position plus the previous velocity times the time interval between 
frames (∆ݐ).  The system is assumed to be driven by changes in the velocity corresponding to 
samples of a zero-mean Gaussian random variable, ݑሺ݊ሻ whose variances, (ߪ௨,௛ and ߪ௨,௩) must 
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be estimated based on the expected target motion.  The state equation for our Kalman filter is 
therefore: 
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Equation 4.2 
Observation of the system is through estimates of the horizontal and vertical positions from our 
block matching algorithm ( ത݄ሺ݊ሻ and ̅ݒሺ݊ሻ). These estimates are assumed to be accurate, but 
corrupted by zero-mean Gaussian noise, ݓሺ݊ሻ whose variances, (ߪ௪,௛ and ߪ௪,௩) must be 
determined based on the current imaging quality.  The observation equation for our Kalman filter 
is therefore: 
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Equation 4.3 
For a given scenario, the variances of the driving force and observation noise are the only 
independent variables and must be tuned by analyzing video and tracking performance of the 
system in each individual treatment, before delivering histotripsy therapy.  The Kalman filter 
recursion then produces the final estimate of the new target position based on a weighted average 
of the result of the search algorithm with an estimate of where the target should be based on its 
previous position and velocity. This final position estimate is then passed through a custom 1 
MB/sec universal serial bus (USB) communication link (FT245BL, Future Technology Devices 
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International Ltd., Glasgow, UK) to the histotripsy therapy array controller to adjust the therapy 
focus to the target’s new estimated position in less than 1 ms. 
Histotripsy Therapy System 
 Histotripsy therapy was delivered by a 1 MHz high power ultrasound annular array 
transducer (Imasonic, SA, Besançon, France). This transducer is composed of 16 equal-area ring 
elements aligned confocally on a spherical segment, allowing axial focal steering. The transducer 
had a 100mm aperture and was geometrically focused at 90mm (f# = 0.9), with a 40mm central 
hole to accommodate an imaging probe. The annular array was driven by custom hardware, 
implemented on a field programmable gate array (FPGA, Cyclone II, Altera Corp., San Jose, CA, 
USA) with USB connectivity to control the ultrasound therapy output parameters in real-time. 
Focal patterns for axial foci between 80 and 100 mm with 0.5 mm spacing between adjacent foci 
were programmed and stored in the FPGA. During therapy, the therapy controller can then 
change the transducer focus position to any position within these pre-programmed locations in 
less than 1 ms. This driver output was then routed to custom high-power amplifiers built in-
house and electronically matched to the load transducer.  
In all in vitro experiments, the transducer was driven at the same input voltage level, 
corresponding to peak negative/positive pressures of -21.2/88.5 MPa in free field at the 
geometric focus. This was measured with a fiber optic probe hydrophone [22]. A pulse duration 
of 3 cycles was used for calibration to prevent cavitation at the fiber tip, while still achieving the 
same peak pressures as longer pulses since the transducer ring up period comprises 3 cycles. An 
example of measured pressure waveform is shown in Figure 4-3a. The effect of axial focus 
steering on the pressure is illustrated in Figure 4-3b, where the ratio of the peak negative 
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pressure level relative to that at the geometric focus (90mm) ranges from about 1.06 at 80 mm to 
0.88 at 100 mm. 
 
Figure 4-3: Pressure calibration plots for the therapy transducer. a) Pressure waveform for a 3-
cycle pulse at the output pressure level used in vitro and measured at the geometric focus (90 
mm). b) Peak negative pressure over the axial steering range relative to that at the geometric 
focus. 
4.2.2 In Vitro Tissue Phantom Validation  
This integrated histotripsy therapy system was then tested in three in vitro scenarios using 
tissue mimicking gel phantoms to measure the impact of the motion tracking algorithm on the 
accuracy and efficiency of histotripsy therapy.  First, to evaluate the accuracy at different 
tracking velocities, the target position estimates from the algorithm were compared to the 
position of the target measured from optical images of the moving target during therapy.  The 
optical images were taken at high resolution (30µm pixel size) with a short exposure (2 µs) to 
provide an accurate measurement of the target movement. Second, to evaluate the treatment 
accuracy and collateral damage reduction, the lesion dimensions created in moving phantoms 
with the tracking algorithm were compared to those produced without tracking. Third, to 
investigate the efficiency of the system, the erosion rate (defined as the thickness of the phantom 
 54 
 
divided by the time required to perforate it) in tissue phantoms treated with the tracking 
algorithm enabled were compared to those treated without tracking enabled. 
System Tracking Accuracy at Different Velocities 
To quantify the motion tracking system accuracy, the path of the target was measured by 
imaging the target phantom location using a high speed camera (Phantom V210, Vision Research 
Inc., Wayne, NJ, USA). High resolution images of the target phantom’s range of motion were 
captured through a telephoto lens assembly, resulting in a resolution of ~30 microns per pixel. 
These synchronized images were acquired 60 µsec after the therapy pulse firing to account for 
the acoustic propagation time. The images were then post-processed to produce the reference 
target path for error quantification by comparison with the estimated path stored in the therapy 
controller. 
The target was a 0.18 mm diameter nylon line target embedded in a 1% agarose hydrogel 
inside an acetal housing. This phantom was moved using a Parker XRS positioning system 
(Parker Hannifin Corp., Mayfield Heights, Ohio, USA) over a 15 mm linear path along the 
therapy axis with constant acceleration magnitude of 400 mm/s2 and maximum velocities 
between 10 and 80 mm/s to test the upper limits of the tracking capabilities of the algorithm. 
Varying the pulse duration and pulse repetition frequency (PRF) over the typical histotripsy 
therapy ranges had no effect on the motion tracking frame rate, and therefore accuracy was tested 
only for a single pulse duration and PRF in this study. Histotripsy was delivered using 5 cycle 
pulse duration and 500 Hz PRF for 10 seconds at each of the tested velocities. The estimated 
path was downloaded after each experiment from the FPGA board. The difference between the 
estimated path and path recorded from the high speed images was computed as the tracking error.
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System Treatment Accuracy – Lesion Size 
To quantify the treatment accuracy of the system, the sizes of lesions generated in a 
moving tissue phantom with and without the motion tracking system as well as a stationary 
control phantom were measured and compared. The phantom was moved along the therapy axis, 
and histotripsy therapy was applied to the phantom both with and without motion correction. The 
initial resting position of the line target was aligned with the geometric focus of the therapy 
transducer. Motion was programmed using the Parker XRS positioning system, with constant 
acceleration of 60 mm/s2 over displacements of 5, 10, and 15 mm centered at the geometric 
focus of the therapy transducer. These corresponded to maximum velocities of approximately 24, 
34, and 42 mm/s respectively. We could not reliably secure the gel phantom at higher 
accelerations and velocities because the phantom would slide out of its housing at higher 
velocities. The velocities tested here are sufficient to represent the majority of physiological 
organ motion ranges, and provide complementary data to the raw accuracy assessment described 
previously. Control experiments were conducted with no phantom motion and the target line 
placed at the geometric focus.  
A tissue-mimicking agarose gel phantom with an embedded red blood cell (RBC) layer 
was used here to identify the lesion size, because it was shown to produce reliable estimates of 
the cavitation-induced damage zone. In this phantom, The RBC area lysed by histotripsy 
changed from opaque red to translucent pink [23], allowing direct visualization and evaluation of 
the lesion size. In this experiment, a 5% RBC layer in a 1% agarose gel phantom was made using 
the methods described in the paper. The lesions in the treated phantoms were photographed and 
post-processed to quantify the length and area of the lesion. The images were segmented using a 
local intensity threshold to distinguish the lighter treated lesion areas from the darker, intact red 
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blood cells surrounding the lesions. The length and area of the lesions generated with and 
without motion tracking were computed and normalized by the length and area of the 
corresponding control lesion to allow fair comparison between samples. The methods to segment 
the lesion and calculate the length and area of the lesion are detailed in [23].  
In this experiment series, a line target was embedded perpendicular to the RBC layer to 
provide a distinguishable target in the otherwise acoustically uniform gel phantom. Histotripsy 
pulses at 10 cycle duration and 50 Hz PRF were applied for 2 minutes. This parameter 
combination was used because it has achieved effective fractionation in RBC phantoms in 
previous experiments [23].  
System Treatment Efficiency – Erosion Rate  
To evaluate the efficiency of the integrated system, the rate at which a moving gel 
phantom layer was perforated (erosion rate) using histotripsy with and without tracking was 
measured and compared (sample size = 3). To mimic an in vivo scenario where the perforation in 
the atrial or ventricular septum in the heart was generated using histotripsy a mobile tissue 
membrane phantom between two fluid chambers was developed. Agarose gel at 2.5% 
concentration by weight was formed into discs roughly 3-4 mm thick and 30 mm in diameter, 
with graphite embedded in the gel at 2% concentration to provide both ultrasound speckle and 
visualization of lesion generation. The gel disc was adhered over the center hole of a latex 
membrane sealing the top of a hollow cylindrical chamber (Figure 4-4), allowing direct fluid 
access on both sides of the gel disc. A pulsatile pump (Model 1423, Harvard Apparatus, 
Holliston, MA) was linked to the chamber to pump water into and out of the sealed cylinder, 
displacing the gel phantom, mimicking the in vivo cardiac tissue motion. The displacement and 
velocity could be tuned by adjusting the stroke volume and stroke rate of the pump, resulting in 
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movement strictly along the therapy axis between 3 and 12.5 mm at speeds up to 60 mm/s. 
Movements of 3, 5, 7, 10 and 12.5 mm at a maximum velocity of 40 mm/s were used. 
 
Figure 4-4: Diagram of the phantom apparatus used to evaluate erosion rates. Water was pumped 
into and out of an acrylic cylinder, flexing the latex membrane top, creating motion along the 
axis of the cylinder. A gel or tissue sample was adhered over the center hole of a rigid mounting 
ring in the center of the latex top. 
To quantify erosion rate, the phantoms were treated with 5 cycle histotripsy pulses at 1 
kHz PRF to mechanically erode the proximal surface of the gel phantom, expelling the 
fractionated gel and graphite fragments into the surrounding liquid, eroding a visible flow 
channel through the phantom. These parameters were chosen as they have been used to 
successfully generate perforation in the atrial or ventricular septum in the heart in our previous in 
vivo studies [3, 4]. The erosion rate was computed as the thickness of the gel membrane phantom 
divided by treatment time required to create a visible channel through the opaque gel phantom. 
Control experiments were performed with the same setup with no phantom motion.  The erosion 
rates produced with and without motion correction were compared at identical displacements. 
 
 58 
 
4.2.3 Ex Vivo Tissue Validation  
To validate the in vitro erosion rate results, a proof of concept experiment was conducted 
with excised porcine atrial wall tissue.  The tissue was harvested from fresh porcine hearts 
obtained from a local supplier on the day of the experiment. Four samples of approximately 10 
by 20 mm were mounted to the same apparatus as the in vitro erosion rate experiment (Figure 
4-4), with the pump stroke volume set to achieve a maximum motion displacement of 10 mm. 
Three locations (separated by 8 mm laterally) on each tissue sample were exposed to 5 cycle 
histotripsy pulses at 1 kHz PRF.  Three scenarios were tested: control with no motion, motion 
without tracking, and motion with tracking. Histotripsy therapy was applied until perforation was 
achieved, with the treatment time and resulting erosion rate recorded. 
 
4.2.4 In Vivo Validation 
The procedures described here were reviewed and approved by the University Committee on Use 
and Care of Animals at the University of Michigan (UCUCA). For in vivo proof of feasibility, 
the system was tested on tracking and treating the atrial septum in a single animal open-chest 
canine heart model. Although the ultimate clinical application would be non-invasive (either 
transcostal or subcostal acoustic windows) and not require surgery, this animal model and setup 
were used previously [2] for atrial septal defect (ASD) creation (perforation through the atrial 
septum) using histotripsy and was suitable to test the motion tracking system. A motion range 
(5.2 to 17.1 mm axial displacement) was observed previously for the atrial septum. Therapy 
access to the heart was achieved through a midline sternotomy with retraction of the ribcage. The 
lungs were retracted laterally to prevent interference with ultrasound propagation and the 
pericardium was left intact.  A temperature-controlled, degassed water bath enclosed in a thin 
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plastic bag was coupled to the pericardium with ultrasound gel. The coaxially mounted imaging 
and therapy transducers were submerged in the water bath outside the heart, and positioned 
under ultrasound guidance to center the geometric focus of the transducer over the approximate 
center of the atrial septum’s motion path. A reference image of the atrial septum was acquired 
prior to the histotripsy therapy and used to set up initial motion tracking parameters. After the 
motion tracking algorithm and parameters were tuned, histotripsy pulses of 5 cycles at 1 kHz 
PRF were applied for 10 exposures at 3 different locations on the front, middle and back of the 
atrial septum, totaling 24 minutes of therapy. 
 
4.3 Results 
4.3.1 Motion Tracking System Performance  
The integrated motion correcting histotripsy therapy system achieved a maximum frame 
rate of 62 Hz. The system is capable of tracking targets up to the highest velocity (80 mm/s) and 
highest acceleration (400 mm/s2) tested. The status of the motion tracking was monitored by the 
operator in real-time through an overlay of the estimated target position on the ultrasound image. 
In two cases of the 15 erosion rate trials, and in three of 10 individual treatments in the in vivo 
study, the system encountered significant out-of-plane motion, imaging artifacts or other 
anomalies resulting in a loss of target tracking, in which cases the operator immediately halted 
therapy and reset the tracking to the intended target. 
 
4.3.2 In Vitro Tissue Phantom Validation  
System Accuracy vs. Tracking Velocity 
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Estimated paths from the motion tracking system and the measured paths taken from the 
high speed camera were collected at 500 Hz PRF therapy at a fixed acceleration magnitude of 
400 mm/s2 and velocities between 10 and 80 mm/s. The root mean squared (RMS) and 
maximum error between the two paths over 10 second captures for each scenario is presented in 
Table 1. The RMS accuracy for the motion tracking system over the tested velocity range was 
0.52 mm, which is very close to the 0.5 mm step size of the therapy focus steering. 
Table 4-1: RMS and Maximum Error versus Velocity 
Maximum Velocity  
 (mm/s) 
Error (mm) 
RMS Maximum 
10 0.25 0.65 
20 0.31 1.05 
30 0.41 1.74 
40 0.51 1.75 
50 0.58 2.18 
60 0.63 2.04 
70 0.64 2.26 
80 0.66 2.96 
 
An example plot of the estimated path versus the measured path is shown in Figure 4-5 
for two velocity scenarios. At lower velocities error is dominated by the steering step size, as the 
transducer was only programed with foci at 0.5 mm separations, producing an RMS error less 
than 0.51 mm. This focal step size could be arbitrarily decreased to reduce this source of error, 
however this was not practically necessary since 0.5 mm is already small compared to the bubble 
cloud’s axial extent (25 mm). At higher velocities, the error is above the 0.5 mm step size with 
RMS error up to 0.66 mm at 80 mm/s velocity, with the estimated position trailing the actual 
path in time. At these high velocities, the motion during the algorithm processing time latency 
(averaging 16 ms) between image acquisition and the resulting focal update becomes substantial, 
increasing tracking error. 
 61 
 
 
Figure 4-5: Plots of the estimated and actual motion paths for velocities of 10 and 80 mm/s. 
System Accuracy - Lesion Size 
 The area and length of the lesions created by the histotripsy system in a moving gel 
phantom with and without using motion correction were measured. Lesion area and length data 
were collected for 3 samples at each of the displacements 5, 10, and 15 mm. The lesion images 
were segmented using local pixel intensity thresholds; an example image before and after 
segmentation is shown in Figure 4-6. 
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Figure 4-6: Lesion images before (a) and after (b) threshold image segmentation revealing, from 
left to right, control (C), motion tracking (M) and no tracking (N) lesions for a displacement of 5 
mm. 
From these segmented images, the area and length of motion tracking and no tracking 
lesions were computed as percentages of the dimensions relative to their corresponding control 
lesion (Figure 4-7). The area and length of the lesions generated in the moving targets using 
motion tracking were comparable to those generated with stationary targets. The mean 
percentages of the lesion areas with respect to the control lesion were 93.0%, 100.0% and 92.0% 
using motion tracking at displacements of 5, 10 and 15 mm, respectively. Similarly, the mean 
percentages of the lesion lengths with respect to the control lesion were 99.2%, 100.0% and 
88.8% using motion tracking at displacements of 5, 10 and 15 mm, respectively. In comparison, 
the lesions generated without motion tracking were significantly larger, and the total lesion area 
and length increased with increasing displacement. The mean percentages of the lesion areas 
with respect to the control lesion were 128.5%, 166.5% and 194.1% without motion tracking at 
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displacements of 5, 10 and 15 mm, respectively. The mean percentages of the lesion lengths with 
respect to the control lesion were 137.9%, 166.7% and 197.6% without motion tracking at 
displacements of 5, 10 and 15 mm, respectively. The t-tests revealed that both the lesion area and 
length without motion tracking are significantly larger than their corresponding control lesion (p 
< 0.05), whereas lesion area and length with motion tracking are not significantly larger than 
their corresponding control lesion (p > 0.3). 
 
Figure 4-7: Lesion area and length compared with control (% of control) versus target 
displacement for lesions generated with motion tracking (square) and without motion tracking 
(diamond). 
System efficiency - Erosion Rate  
 The erosion rate of a 2.5% agarose hydrogel membrane phantom was computed for each 
of the motion displacements 3, 5, 7.5, 10, and 12.5 mm with and without motion tracking (N = 3). 
Control experiments were conducted without motion (N = 3) resulting in an erosion rate of 
3.03±0.14 mm/min, representing the maximum erosion rate for this scenario. A plot of erosion 
rate versus motion range is presented in Figure 4-8. A two-sample t-test shows that the erosion 
rate with motion tracking was significantly higher than the erosion rate without motion tracking 
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(p < 0.05) for all displacements. Erosion rate with tracking for all displacements averaged 
2.7±0.29 mm/min, or approximately 89.0% of the control rate (p < 0.05). Without tracking, 
erosion rate was substantially reduced to between 1.8±0.07 mm/min for the 3 mm displacement 
(61.6% of the control rate) and 0.91±0.14 mm/min for the 12.5 mm displacement (30.0% of the 
control rate) (p < 0.05). Differences in erosion rate among the individual displacements for the 
motion tracking case were not significant (p > 0.05), except between the 3 mm and 7.5 mm 
displacements (p = 0.03) due to a low observed variance in those specific samples. 
 
Figure 4-8: Erosion rate versus target phantom displacement for control without motion 
(diamond), motion tracking with motion (square) and no motion tracking with motion (circle). 
(N = 3). 
4.3.3 Ex Vivo Tissue Validation Results 
Erosion rate in ex vivo atrial wall tissue was measured for a 10 mm motion range (N = 4). 
An erosion rate of 4.51±0.89 mm/min was achieved for the control case (stationary target). 
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Erosion rate with motion tracking was measured at 4.40±0.82 mm/min which was comparable to 
the control rate, (p = 0.86; t-test; 97% of control rate). Erosion rate without motion tracking was 
measured at 1.90±0.39 mm/min or 42% of the control rate, which was significantly lower than 
both the control and motion tracking rates (p < 0.01; t-test). 
 
4.3.4 In Vivo Feasibility Results 
In the in vivo experiment, the motion tracking system successfully tracked the motion of 
the atrial septum in the live beating canine heart at 3 separate locations. The atrial septum was 
observed to move over a maximum displacement of 8 mm due to the 14.1±2.1 breaths per minute 
respiration and 116.6±11.0 beats per minute heart rate. A frame rate of 32.6±5.6  Hz was 
achieved for accurate motion tracking, which was lower than that in the in vitro case due to the 
increased imaging time required for the 5 steered plane wave acquisitions needed to improve 
imaging quality. An excerpt of the estimated target path recorded during treatment is plotted in 
Figure 4-9. The path shows the expected short, quick movements of the septum from cardiac 
motion added with the larger, slower movements from respiration. 10 treatments totaling 24 
minutes of therapy were applied to the septum, generating a targeted lesion on the atrial septum 
as shown by ultrasound in Figure 4-10. Since this was a procedural feasibility study, the animal 
was euthanized immediately following therapy. Histological confirmation of a lesion created by 
histotripsy is shown in the Hematoxylin and Eosin (H&E) stained slide of the treated atrial 
septum (Figure 4-11). Distinctive borders of injury and slight areas of flanking hemorrhage at the 
boundary were observed. Wound healing and long-term effects of therapy could not be evaluated 
with this study. 
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Figure 4-9: Plot of the estimated axial position of the target on the canine atrial septum during 
treatment. 
 
Figure 4-10: Ultrasound images of the atrial septum before therapy (left) and after therapy (right) 
showing significantly reduced echogenicity across the treated region of the atrial septum, 
corresponding to regions of damaged or removed tissue. LA = left atrium; RA = right atrium. 
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Figure 4-11: Hematoxylin and eosin-stained slide of treated atrial septum (C) along with close-
up images of the fractionated region (A) and surrounding untreated region (B). 
4.4 Discussion 
The main advantage of the system developed here over previously developed ultrasound 
therapy system with motion correction is that it requires no specialized hardware for 
implementation. To implement a system similar to the successful motion correcting ultrasound 
therapy systems demonstrated previously [8, 9], a 2D phased array therapy system with both 
transmit and receive capabilities would have to be developed along with corresponding multi-
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channel data-acquisition hardware. Similar to another recently developed motion correction 
system [10] our integrated therapy motion correction utilized ultrasound images directly for 
target motion tracking. The optical flow techniques from that work are aimed at slower moving 
abdominal organs, and the resulting lower frame rates (8 Hz) are likely not sufficient for high 
speed cardiac motion. Another advantage of reference image or landmark based tracking 
methods like these is that they allow the flexibility to utilize image features that are arbitrarily 
shaped and positioned, and avoids the risk of error compounding over time inherent in relative 
motion tracking methods. For example, frame to frame speckle tracking methods can allow small 
estimation errors from each frame to compound over time, potentially degrading accuracy over 
time as the tracked location “drifts”. Our method uses a single reference image for all motion 
estimates, where the reference feature is either found and the system remains accurate, or an easy 
to identify tracking error occurs, and therapy can be halted. If the tracked feature is within the 
treated volume, however, the reference image will need to be recaptured as the treatment 
progresses, as the appearance of the reference will change when that volume is fractionation by 
histotripsy. 
The current system is not without limitations. In this study, the algorithm tracks the 
motion in 2D based on ultrasound images, while therapy focus steering is only performed in the 
axial dimension. This limited dimensionality is useful for correcting the motion encountered in 
the neonatal and fetal cardiac applications that we are currently investigating, where the only 
significant motion is along the therapy axis. However, future applications in the adult heart will 
likely require 3D motion correction. Extensions of the key components of our system (diamond 
search, SAD criterion, and Kalman filtering) to a 3D motion correction system are 
straightforward with the use of 3D ultrasound data or two orthogonal 2D image planes. Though 
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computational complexity is the major concern for the extension of the block matching method, 
it potentially can be mitigated with appropriate choices of imaging field of view, reference block 
size, and search procedure. For example, a potential 3D Diamond Search pattern would only 
require 19/6 test points in LDSP/SDSP versus the current 9/4 in 2D. Furthermore, processing 
hardware upgrades and computation parallelization may potentially offset these additional 
requirements, and we anticipate sufficiently high maximal tracking velocity can be achieved for 
cardiac therapy. Other 3D ultrasound motion tracking methods have been demonstrated  [24, 25], 
and will be evaluated as potential alternatives to the proposed block matching estimation for 
improved tracking of the non-rigid motion of heart structures. With these improvements, the 
system’s performance could be more directly compared with previous work on 3D motion 
correction for ultrasound therapy and evaluated for its utility in high speed targets for cardiac 
therapy. 
Other improvements, intended to enhance clinical applicability and ease of use, include 
automatically halting therapy when tracking is lost, as detected by the SAD metric dropping 
below a threshold value. Also, as the cavitation bubble cloud is the effective “scalpel” in 
histotripsy treatment, an algorithm incorporating simultaneous bubble cloud tracking will help 
evaluate the effectiveness and accuracy of the motion tracking during histotripsy therapy.  More 
precise adjustments could then be made based on this feedback to further improve the therapy 
efficiency and accuracy if necessary.  
The in vivo experiment used an open-chest adult canine model, which provided cardiac 
motion for our feasibility study. Our current goal is to implement the motion tracking method for 
pediatric cardiac applications, including perforation of the atrial septum in the neonatal patients 
with hypoplastic left heart syndrome (HLHS). In these pediatric patients, a subcostal acoustic 
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window exists to access the atrial setup without lung or rib obstruction. Unfortunately this 
acoustic window does not exist in non-primate animals, as their heart orientation is different 
from humans. We have utilized transthoracic histotripsy to create cardiac lesions in neonatal 
animal models, but partial lung and rib obstruction was encountered [3, 4]. Even though 
histotripsy has been shown to be able to generate precise lesions through ribs without aberration 
correction [26], the lungs full of air in the ultrasound pathway still pose a serious problem. 
Therefore, to access the atrial septum, an open-chest surgery was performed in this initial 
feasibility study. In the future, we plan to augment the animal model to create access to the atrial 
septum through an intact chest (e.g., by filling the lung with fluid), which will allow us to test 
non-invasive histotripsy cardiac therapy integrated with motion tracking without the need to 
perform open-chest surgery. In addition, to further improve the imaging quality, we also plan to 
redesign our therapy transducer to allow the imager to be directly placed on to the patient’s skin 
to avoid imaging quality degradation caused by stand-off distance between the imager and the 
skin. With all these improvements, this motion tracking system can be a valuable tool for 
histotripsy therapy on moving targets, such as cardiac applications to create intra-cardiac 
communications in infants with congenital heart disease or the removal of excess myocardial 
tissue such as that found in adult patients with hypertrophic cardiomyopathy. 
 
4.5 Conclusion 
This study has been our first attempt to integrate a motion correction scheme into a 
histotripsy system to track the motion of a cardiac target during histotripsy therapy. Our results 
indicate that the block matching method using diamond search algorithm and Kalman filtering is 
capable of tracking fast motion with high accuracy. When treating a moving target in vitro, 
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significant improvement in therapy accuracy and efficiency was achieved compared to therapy 
without using the algorithm. Though in vitro testing phantoms could not produce the non-rigid 
motion present in the heart, feasibility was evaluated in a live beating heart in vivo with further 
work necessary to quantitatively evaluate the system performance in this setting and adapt the 
system for non-invasive therapy. 
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Chapter 5 
 Bubble-induced Color Doppler Feedback for Histotripsy Tissue 
Fractionation  
A majority component of this chapter is excerpted from a manuscript that is being prepared for 
IEEE Transactions on Ultrasonics, Ferroelectric, and Frequency Control. 
 
5.1 Introduction 
 Real-time imaging feedback during minimally invasive or non-invasive ablation therapy 
is essential for ensuring efficient and thorough treatment of the target tissue. The fractionation 
induced by histotripsy appears as a hypo-echoic zone on B-mode ultrasound images, resulting 
from the backscatter amplitude reduction due to reduced number and size of scatters [1]. 
Although this is only observed when substantial tissue fractionation is generated, and the level of 
reduction corresponding to treatment completion varies significantly across subjects. [2]. 
Magnetic resonance (MR) imaging has also been investigated and histotripsy lesions can be 
shown on standard T1- or T2- weighted images [3]. MR is sensitive to histotripsy-induced tissue 
damage, where T2-weighted images can detect apparent changes after only a few therapy pulses 
have been applied. The high cost of MR imaging systems, the slower frame rate, and the 
requirement for MR compatible ultrasound therapy transducers are potential limiting factors. 
Elastography has also been explored to monitor histotripsy therapy, as histotripsy fractionation 
results in increasingly softer tissue. With comparatively low cost and ease of integration, 
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ultrasound elastography [4-9] is an attractive choice for histotripsy feedback. Ultrasound 
elastography has been widely investigated for tissue delineation because the high contrast in the 
elasticity between normal and diseased tissues allows higher specificity and sensitivity for 
disease diagnosis [10-12]. Wang et al.’s work has demonstrated shear wave elastography is more 
sensitive at detecting early-stage histotripsy fractionation compared to echogenicity decrease 
[13].  However, in that work, to measure a shear wave velocity reliably, the treatment needs to be 
halted temporally to allow the application of additional push pulses and the measurements of 
shear wave velocity. 
Color Doppler imaging, synchronized with histotripsy pulses has been observed to detect 
motion in the focal volume during the time immediately after the therapy pulse arrives at the 
focus (Figure 5-1). The velocity detected at a fixed delay after the therapy pulses was observed 
to change in magnitude and even direction over the course of histotripsy therapy.  
  
Figure 5-1: Color Doppler overlaid on B-mode images during a histotripsy treatment of ex vivo 
porcine liver. Doppler velocity was observed to transition from towards the therapy transducer at 
the start of treatment (left) to away from the transducer later in the treatment (right) in fixed 
delay, synchronized color Doppler imaging. 
This motion is only detectable when a cavitation bubble cloud is formed, and therefore we have 
termed it bubble-induced motion. This motion can last over 20 ms after each histotripsy pulse. 
The motion itself likely results from some net force exerted by rapid bubble expansion or 
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collapse in the focal region, though the precise mechanism(s) that cause it are not clear. This 
force generates a variable motion response depending on mechanical properties of the tissue in 
the focal region. This is similar to the dynamic stress applied in some forms of elastography, and 
could provide similar information about the focal tissue mechanical properties. We hypothesize 
that direct metrics of the changing motion parameters over the course of histotripsy therapy may 
be directly correlated with fractionation progression and can be detected by ultrasound color 
Doppler during the histotripsy treatment. The residual cavitation nuclei can persist for over 100 
ms after the cloud collapse and provide strong acoustic scattering for Doppler acquisitions of 
bubble-induced motion in the treatment focal region. 
This chapter investigates the characteristics of metrics gathered from this color Doppler 
velocity feedback of bubble-induced motion during the histotripsy treatment and correlates them 
to the degrees of tissue fractionation generated by histotripsy. Three experiments were performed. 
First, the bubble-induced motion was recorded and characterized using both acoustic and optic 
methods. The motion in the treatment focal region after each histotripsy therapy pulse was 
generated in transparent tissue-mimicking agarose phantom and estimated using ultrasound color 
Doppler and particle image velocimetry (PIV) processing of simultaneous ultrasound and high-
speed optical images of the focal region. The profiles of the Doppler and PIV velocity were 
compared over the course of the entire histotripsy treatment to analyze and characterize the 
motion. Second, the change in the temporal profile of Doppler velocity of the bubble-induced 
motion is correlated with the level of fractionation generated in tissue-mimicking phantom over 
the course of the histotripsy treatment. Finally, the same color Doppler acquisitions were 
performed in ex vivo porcine liver tissue to validate this correlation in real tissue. To evaluate the 
potential of using bubble-induced color Doppler feedback for real-time histotripsy monitoring, 
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we also investigated metrics to quantify the temporal profile of the bubble-induced motion that 
can be measured and processed during the histotripsy treatment. 
 
5.2 Methods 
5.2.1 General Methods 
1. Histotripsy Therapy 
Histotripsy therapy pulses of 2 cycle pulse duration at > 30 MPa peak negative pressure 
were applied over a 6mm cube using a 500 kHz phased array transducer built in-house. The 
transducer is composed of 32 elements with 50 mm diameter mounted confocally on a 15 cm 
hemispherical shell. The array is driven by a custom-built 32-channel amplifier system that 
controls the driving amplitude and phase of each individual element. To ensure uniform 
fractionation over the target volume, 219 focal points at 1 mm separations were treated 
sequentially at 150 Hz with a single pulse applied at each location. These focal locations were 
arranged into layers separated by 1 mm in the axial dimension, with alternating layers offset in 
both lateral dimensions from adjacent layers by half the lateral spacing (Figure 5-2). This 
treatment strategy provides complete coverage of the treatment area with fewer focal locations 
and less treatment overlap than a simple rectilinear scan due to the roughly ellipsoidal bubble 
cloud shape. This process was repeated every 1.5 seconds until all focal locations had been 
treated with up to 2000 pulses each. Using this pulsing strategy, all 219 foci are treated in 
parallel, at a constant rate of 0.67 Hz. This pulsing strategy guarantees uniform therapy dose over 
the treatment volume at all times during treatment. 
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Figure 5-2: Steered focal locations for the 219 foci with 5 alternating 1mm spaced axial layers of 
7x7 foci and 6x6 foci. The axial layers are separated by 1mm, but with the 6x6 grids offset from 
the 7x7 layers by 0.5mm in both lateral dimensions. 
2.  High Speed Optical Imaging 
High speed optical images of the focal region were captured using a Phantom V210 with 
135mm macro lens on bellows with backlighting (Vision Research, Wayne, NJ). The camera and 
backlight were positioned perpendicular to the therapy axis (Figure 5-3). The camera was set to 
capture either a single image per therapy pulse, or acquisition sets of 200 images at 10 kHz frame 
rate beginning immediately after the firing of a therapy pulse. For the 200 image per pulse 
acquisition mode, the internal memory of the camera could not accommodate acquisitions after 
every therapy pulse, so to facilitate continuous treatment without interruptions for data transfer; 
acquisition sets were captured after every 10th pulse delivered to the center focal location. 
3.  Doppler Ultrasound Imaging 
Ultrasound Doppler acquisitions were performed using a Verasonics imaging system 
(Seattle, WA) with a 5 MHz linear imaging transducer (ATL HDI L7-4, Philips, Andover, MA). 
The imaging transducer was positioned opposite the therapy transducer, aligned along the 
therapy axis, i.e., the ultrasound imaging beam was rigidly aligned with the therapy beam to 
avoid the effect of angle variation on Doppler (Figure 5-3). The ultrasound imaging system was 
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set to capture acquisition sets of 200 Doppler acquisitions at 10 kHz pulse repetition frequency 
(PRF) rate beginning immediately after the firing of a single therapy pulse. Acquisition sets were 
captured after every pulse delivered to the center location, and therefore included Doppler 
acquisitions simultaneous to the optical images acquired after every 10th pulse for direct 
comparison. 
 
Figure 5-3: Experimental setup with 500 kHz transducer mounted to the side of a water tank with 
5 MHz imaging probe mounted opposite the therapy and aligned along the therapy axis. The 
Phantom high speed camera was positioned perpendicular to the therapy axis. 
5.2.2 Experiment 1 – Bubble-induced Motion Characterization using PIV and Doppler  
1. Agarose Tissue Phantom Preparation and Treatment 
To characterize the bubble-induced motion after each histotripsy pulse through the entire 
histotripsy treatment, experiments were performed on optically and acoustically transparent agar 
tissue mimicking phantoms. The purpose of this phantom is to allow simultaneous optical and 
acoustic interrogation of the focal volume for motion analysis during histotripsy treatment. Agar 
powder (AG-SP, Lab Scientific, Livingston, NJ) was dissolved in heated distilled water at 1.5% 
concentration by mass. The solution was then degassed in a vacuum chamber and allowed to 
cool and solidify in an acrylonitrile butadiene styrene (ABS) plastic housing frame with thin 
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polycarbonate walls. The phantom was treated at 3 locations with 941 histotripsy pulses using 
the previously described methods and parameters. These treatments were monitored using the 
described optical and ultrasound imaging methods for PIV and Doppler velocity estimation. In 
this experiment, 200 optical images were acquired after every 10th therapy pulse for PIV 
analysis, and 200 Doppler acquisitions were collected after every therapy pulse, both at 10 kHz 
frame rate. 
2. PIV Velocity Estimation 
The high-speed optical images of the focal region were processed using the freely 
available PIVlab package (1.32) for MATLAB to estimate the motion resulting from the 
histotripsy therapy pulses. The PIV analysis was performed in a roughly 6.6 × 3.3 mm field of 
view at a resolution of 116 pixels per mm (total 768 x 384 pixels).  The images were processed 
in pairs at two subsequent time points using a FFT window deformation algorithm  with 3 pass 
velocity estimation with image block sizes and step sizes of 64/32 pixels for pass 1, 32/16 pixels 
for pass 2, and 16/8 pixels for pass 3. This resulted in velocity field maps of the field of view 
over the 19 ms after a histotripsy therapy pulse. The axial components of these PIV velocity 
maps were then spatially averaged over the 2 x 4 mm bubble cloud area, and temporally 
averaged over a 1 ms rolling window to produce an average velocity estimate in the focal region 
over time to compare with that measured by color Doppler.  As the optical images have higher 
resolution than the acoustic images, the motion estimated from PIV is considered as the gold 
standard that we can use to compare with the Doppler Velocity estimation.  
3.  Doppler Velocity Estimation 
The ultrasound Doppler acquisitions were processed offline using the Doppler processing 
algorithm included in the Verasonics imaging system. To calculate the velocity over the 19 ms 
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after the therapy pulse, the 200 acquisitions were processed in rolling 10 acquisition segments 
(equivalent to making 190 separate 10 frame acquisitions at 10 kHz PRF with delay times of 
integer multiples of 100 ns after each histotrispy pulse). These Doppler velocity maps were then 
spatially averaged over the 2 x 4 mm bubble cloud area to produce the final average velocity 
estimate over time. The motion profiles as measured by color Doppler can then be compared to 
those measured by direct optical interrogation to determine if color Doppler acquisitions can 
provide an accurate measure of histotripsy bubble cloud induced motion. 
From both the PIV and Doppler dataset, a metric was extracted to capture the changes of the 
temporal profile of the bubble-induced motion over the course of therapy into a single number. 
PIV and Doppler images observe a coherent motion pushed away from the therapy transducer 
and rebounded back. The metric used is the time to peak rebound velocity (tPRV), which was 
computed by calculating the time of the highest magnitude negative velocity after each therapy 
pulse. This metric was computed from both the PIV and color Doppler velocity measurements 
for comparison. 
 
5.2.3 Experiment 2 – Correlate Bubble-induced Color Doppler with Histotripsy Tissue 
Fractionation in Agarose Tissue Phantom  
1. Damage-indicating Agarose Phantom Preparation and Treatment 
The purpose of this phantom is to include a quantifiable damage indicator of histotripsy 
tissue fractionation to correlate with a feedback metric extracted from the color Doppler velocity 
estimations. Tissue-mimicking agarose gel phantoms embedded with a thin layer of red blood 
cell (RBC) have been shown to produce reliable estimates of the cavitation-induced fractionation, 
where the RBC area turns from opaque to translucent pink as the RBCs are fractionated and can 
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be visualized directly during the treatment [14]. To form the 3 layer phantom, agar powder was 
dissolved in heated, phosphate-buffered saline solution at 1.5% concentration by mass. This 
solution was degassed and poured to half fill the same ABS housing with thin polycarbonate 
walls. This was allowed to solidify to form a bottom layer of transparent agarose. Red blood cells 
were then added to small amount of agarose solution at 5% concentration by mass. This was then 
poured onto the base layer of transparent agarose in an approximately 1mm thick layer and 
allowed to solidify. Finally, a top layer of transparent agarose was added to fill the housing and 
fully contain the RBC layer in a large tissue-mimicking phantom. 
The ultrasound imaging and high speed optical imaging setup was identical to the 
previous experiment, with color Doppler and optical interrogations performed following the 
therapy pulse delivered to center focal location after each full treatment of the therapy volume. In 
this case however, only a single optical image was captured per therapy pulse. The phantom was 
positioned with the RBC layer parallel to the therapy propagation and perpendicular to the high 
speed imaging to visualize the lesion development over the course of therapy. The phantom was 
treated at 3 locations with 1000 histotripsy pulses each using the previously described methods 
and parameters.  
2.  Fractionation Progress Estimation 
From images of this lesion progression, we can create a reference metric of fractionation 
progression and use it to correlate with the tPRV Doppler feedback metric. To compute this 
reference metric, an approximately 4mm square region of interest was chosen in the center of the 
treated region and the average pixel intensity was computed over the treatment course. The red 
blood cell layer allows more light to pass through as it is increasingly fractionated, eventually 
becoming completely transparent when all cells in the layer have been destroyed. The mean 
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lesion intensity (MLI) in the region of interest can therefore directly measure the fractionation 
progression in that region, and can serve as a reference metric of fractionation progression. This 
metric was computed for the three treatments and correlated to the fractionation metric extracted 
from the color Doppler velocity feedback (tPRV) to determine its sensitivity in detecting 
histotripsy fractionation damage in the RBC tissue phantom. 
 
5.2.4 Experiment 3 – Validate Bubble-induced Color Doppler in Ex Vivo Porcine Liver 
A final experiment was conducted in ex vivo porcine liver to validate the bubble-induced 
color Doppler feedback in real tissue. Doppler data were collected throughout the histotripsy 
treatment. Ex vivo porcine liver samples were treated at different therapy doses (i.e., number of 
therapy pulses), with 3 samples per dose. The treated tissue was processed for histological 
analysis, and the degree of tissue fractionation corresponding to a therapy dose was assessed by 
counting the percentage of intact cell nuclei within the treatment region as described below. The 
tPRV metric was computed for these datasets as described earlier. An alternative metric, the fixed 
delay focal mean velocity (FD-FMV), was also computed from synchronized, delayed color 
Doppler acquisitions at high frame rates.  The FD-FMV would therefore be useful for 
applications requiring faster treatment pulsing rates. Both tPRV and FD-FMV were correlated 
with the level of tissue fractionation evaluated histologically. 
1. Tissue Preparation 
Freshly excised porcine liver tissue was acquired from a local supplier, preserved in 
normal saline at 4° C, and used within 24 hours of harvest. Prior to treatment, the liver was 
sectioned into approximately 5 cm cube sections. The sections were placed in degassed saline 
(less than 20% of normal saturation determined by pO2) at room temperature for at least 1 hour 
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to allow for equilibration of the temperature and gas concentration. The liver sections were then 
embedded in 1% agarose in the same ABS framed, polycarbonate walled housing. 
2.  Ex Vivo Tissue Treatment 
Lesions were created in the liver samples with 50, 200, 500, 1000, or 2000 pulses per 
treatment location using the previously described histotripsy setup and therapy parameters. A 
total of 15 samples were treated, resulting in a sample size of 3 for each number of therapy 
pulses. The ultrasound imaging setup was identical to the previous experiments, with color 
Doppler interrogations performed following the therapy pulse delivered to center focal location 
after each full treatment of the therapy volume. This process was repeated every 1.5 seconds 
until all focal locations had been treated with up to 2000 pulses each. The Doppler acquisitions 
were processed identically to the previous experiments to produce a velocity progression over 
the course of histotripsy therapy.  
3.  Assessment of Degree of Tissue Fractionation 
The degree of tissue fractionation was assessed for the lesions produced in the liver 
samples via histology. The liver sections were fixed in 10% neutral buffered formalin and 
processed for hematoxylin and eosin (H&E) staining. Histological sections 5 μm thick were 
made at 500 μm intervals through the lesion with slices oriented in parallel with the ultrasound 
imaging plane. The degree of tissue fractionation was evaluated with the percentage of 
structurally intact cell nuclei remaining in the lesions. This percentage was calculated using the 
method described in [2], and summarized here. The number of structurally intact cell nuclei was 
counted in five 320 μm × 240 μm regions near the center of the lesion, or in an untreated control 
region. An average count was obtained from the five counts. The average count for the lesion 
was then divided by that for the control, producing the percentage of nuclei remaining metric 
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(PNR). This metric was then compared to the fractionation metric extracted from the color 
Doppler velocity feedback (tPRV) to determine its sensitivity in detecting histotripsy fractionation 
damage in tissue. 
 
5.3 Results 
 
5.3.1 Experiment 1 – Bubble-induced Motion estimation using PIV and Color Doppler  
Following each histotripsy pulse, a cavitation bubble cloud was generated immediately 
and collapsed within 300 μs. Residual bubble nuclei persisted for over 100 ms after the 
cavitation collapse and were clearly visible in high-speed optical images of the focal region after 
a histotripsy therapy pulse. These residual nuclei acted as the contrast particles for PIV analysis 
of the bubble-induced motion. PIV velocity maps showed 2 phases of motion during the 20 ms 
after a histotripsy therapy pulse. For up to the first 2 ms, chaotic motion was present, where the 
motion was pointed in all directions in a random manner through this period and was 
inconsistent from pulse to pulse. This chaotic motion phase likely resulted from the violent 
activity of the histotripsy bubble cloud. After this chaotic motion subsides, a coherent motion 
along the direction of the therapy ultrasound beam was visible. The coherent motion was first 
moving away from the therapy transducer, and then rebounding back towards the therapy 
transducer and oscillating Figure 5-4 shows images of an example progression of the focal region 
PIV velocity map after the tissue had been treated with 50 histotripsy pulses. The therapy pulse 
was propagated from right to left. 
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Figure 5-4: High speed images of the focal region 50 pulses into treatment (therapy applied from 
the right) with PIV velocity map overlays showing the histotripsy bubble cloud (top left), chaotic 
motion immediately after the collapse of the bubble cloud (top right), and finally coherent 
motion, including a push away from the transducer (bottom left) and subsequent rebound 
(bottom right). 
Three treatments of 941 pulses were performed in the agarose tissue phantom, with the 
bubble-induced motion following the histotripsy pulses monitored using the PIV and color 
Doppler methods described. Velocity maps collected using both methods show a similar trend, 
with brief chaotic motion followed by push and rebound motion. This trend remained the same 
as the treatment progresses. The duration of these push and rebound motions were observed to 
increase over the course of histotripsy therapy as the tissue phantom was increasingly 
fractionated. The average velocity progression is shown in Figure 5-5 for both PIV and Doppler 
estimation methods. The estimated velocity is shown in color (red is away from therapy 
transducer and blue is towards the therapy transducer) versus the time delay from the onset of the 
therapy pulse (y axis) and the number of therapy pulses (x axis). Both profiles are shown over 
the same limited velocity range (-1 cm/sec to 1 cm/sec) to allow more easy comparison of the 
changes over the course of treatment. 
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Figure 5-5: Comparison plots showing the average velocity estimates from PIV (a) and Doppler 
(b) after every 10 therapy pulses. The plots show velocity (color map) versus time after the 
therapy pulse (y-axis) over the course of therapy (x-axis). 
For further comparison of the bubble-induced velocity estimated using PIV versus color 
Doppler for a specific number of therapy pulse applied, Figure 5-6 shows 3 individual velocity 
traces after 10, 30, and 290 therapy pulses. These traces correspond to vertical lines in the full 
velocity progressions at the specified dose points. After the 2 ms chaotic motion phase, PIV and 
Doppler estimates of the average velocity agree with each other well over the course of treatment 
with a root mean squared (RMS) error of 0.48 ± 0.1 cm/s. These plots show a temporal 
expansion of the velocity profile with increased therapy dose, likely resulting from reduced 
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elasticity as the phantom was increasingly fractionated by histotripsy pulses. For example, tPRV 
was 2.6, 5.4, and 10.8 ms after 10, 30, and 290 pulses, respectively. The increase in the duration 
of the coherent push and rebound motion reached a plateau after roughly 250 pulses, likely 
because the phantom was completely liquefied. 
 
Figure 5-6: Individual velocity plots for the 19 ms after the therapy pulse after 10 therapy pulses 
(left), 30 therapy pulses (center), and 290 therapy pulses (right) showing good agreement 
between PIV and Doppler in measured velocity after the initial chaotic motion. 
The tPRV metric was computed for the velocity profiles obtained from the 3 treatments 
using PIV and Doppler data to further validate the Doppler velocity measurements. Analysis was 
performed on both the raw metric, along with a 5 point (50 pulse) moving average filtered 
version to compare the underlying trend in the progression of the tPRV metric. Figure 5-7 shows 
the mean and standard deviation of the raw tPRV metric from the PIV and Doppler analysis, along 
with the filtered version of each for comparison. tPRV extracted from PIV and Doppler both 
increase with increasing therapy dose. Pulse to pulse variation between the two measurements 
was observed to increase for higher therapy dose (> 250 pulses). Figure 5-8 shows the correlation 
of the raw tPRV metric from both sources, along with the correlation of filtered metric. The pulse 
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to pulse variation clearly reduced the correlation (R2 = 0.74) for the raw metric, however the 
underlying trend is clearly the same from the high correlation of the filtered metric (R2 = 0.95). 
 
Figure 5-7: Plots of the tPRV metric from the PIV analysis (a) and the Doppler analysis (b) with 
mean and standard deviation of the raw metric for every 40th pulse, along with a solid line 
representing the 5 point (50 pulse) moving average (N = 3). 
 
Figure 5-8: (a) Correlation of the tPRV metric from the PIV and the Doppler analysis. Dashed line: 
y = 0.8059•x + 2.673 (R2 = 0.74) (N = 3).  (b) Correlation of the filtered tPRV metric from the PIV 
and the Doppler analysis. Dashed line: y = 0.9261•x + 1.14 (R2 = 0.95) (N = 3). 
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5.3.2 Experiment 2 – Correlate Bubble-induced Color Doppler with Histotripsy Tissue 
Fractionation in Agarose Phantom  
In the agarose tissue phantom, optical images of the RBC layer and Doppler velocity 
profiles were collected after each of the 941 therapy pulses at the center of the treated volume. 
The RBC phantoms showed rapid fractionation for the first 50 pulses, with slower fractionation 
up to 120 pulses, when the lesion became completely transparent. Example images of the RBC 
layer fractionation progression are shown in Figure 5-9 after 10, 25, 100, and 250 pulses have 
been applied to all points in the treatment pattern. 
 
Figure 5-9: Images of the fractionated red blood cell (RBC) layer after 10 (top left), 25 (top 
right), 100 (bottom left), and 250 (bottom right) therapy pulses have been applied to each focal 
point in the 219 point focal pattern. 
The color Doppler velocity progression is shown in Figure 5-10 over the first 500 pulses 
of the treatment. The estimated velocity is shown in color (red is away from the therapy 
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transducer and blue is towards the therapy transducer) versus the delay from the therapy pulse (y 
axis) and therapy dose (x axis). This velocity profile shows the velocity response expand in time 
for increased therapy dose, reaching a plateau after roughly 150 pulses. Additional therapy 
beyond this point generates no further change in the dynamics of the bubble induced motion that 
can be detected by color Doppler acquisitions. 
 
Figure 5-10: Average Doppler velocity profile for the first 500 pulses during the 6 RBC phantom 
ablations. The plot shows velocity (color map) versus time after the therapy pulse (y-axis) over 
the course of therapy (x-axis) (N=6). 
Fractionation metrics were computed from the data for each of the 6 individual RBC 
layer treatments. From the optical images of the RBC layer, the fractionation metric of mean 
lesion intensity (MLI) was computed and is plotted over the course of therapy in Figure 5-11. 
This plot shows saturation of the MLI metric after approximately 120 pulses. At this point, 
images of the lesion show that all the RBC’s in the layer had been destroyed and no further 
information could be obtained with this metric. From the Doppler velocity data, the time to peak 
rebound velocity (tPRV) metric was computed for the motion following each therapy pulse. The 
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tPRV metric can be visualized in the full velocity progression (Figure 5-10) as the time value (y-
axis value) at which the highest negative velocity (darkest blue color) occurs for each value of 
therapy dose (x-axis value). This metric is plotted in Figure 5-11, showing saturation of the tPRV 
metric after approximately 250 pulses, indicating no further change in the bubble induced motion 
following additional histotripsy therapy pulses. Both metrics were computed for all 1000 therapy 
pulses, but are displayed with mean and standard deviation for only every 10th pulse for the first 
250 pulses for clarity. 
 
Figure 5-11: Progression of the MLI reference metric (a) and tPRV metric (b) over the first 250 
pulses of histotripsy therapy in the RBC layer Agarose phantom. Both metrics are plotted with 
mean and standard deviation (N = 6) for every 10th pulse for pulses 1 to 241 for clarity. 
The correlation between these metrics was then computed to determine the validity of the 
tPRV metric to measure the degree of fractionation of the target tissue and is shown in Figure 5-12. 
This analysis was confined to the first 120 pulses, since the reference metric of fractionation 
progress (MLI) saturated at this point, providing no additional information about the 
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fractionation progression for additional therapy. A linear correlation was observed between the 
tPRV metric and the reference MLI metric (R2 = 0.95). 
 
Figure 5-12: MLI metric vs. tPRV metric for the first 120 pulses of therapy in the RBC phantom. 
Dashed line: y = 19.81·x + 36.22 (R2 = 0.95) (N=6). 
5.3.3 Experiment 3 – Validate Bubble-induced Color Doppler in Ex Vivo Porcine Liver 
Representative histology of the lesions produced in the ex vivo liver sections are shown 
in Figure 5-13. In the control regions, all tissue and cellular structures appeared normal and 
structurally intact. Even with only a small number of pulses (50 pulses/treatment location) 
applied, large scale fractionation was apparent in the tissue. While some pockets of cells 
appeared structurally intact with normal appearing cell nuclei, much of the tissue appeared 
damaged with large regions of mostly homogenized tissue visible. At the next measured therapy 
dose (200 pulses/treatment location), nearly all tissue structures and cells were destroyed. Only a 
few scattered nuclei and tissue fragments remained intact. At a large number of pulses (>500 
pulses/treatment location), the treated volume appeared completely homogenized with no 
recognizable tissue structures or cellular components. The tissues outside the lesion volume 
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appeared structurally intact, with only minor damage pockets scattered around the area very near 
the edges of the treated region (< 100 micron). 
 
Figure 5-13: Histological sections of the lesions produced with increasing numbers of therapy 
pulses per treatment location. In the control, all tissue structures and cells appeared structurally 
intact. After 50 pulses, large volumes of acellular debris were observed, with some pockets of 
structurally intact cells and nuclei remaining. After 200 pulses, the entire lesion appeared 
fractionated with few remaining intact nuclei. Beyond this (>500 pulses/treatment location), the 
treated volume appeared completely homogenized with no recognizable tissue structures and 
very few fragments of nuclear material. 
The percentage of nuclei remaining (PNR) metric in the treated volume was plotted 
against the number of therapy pulses in Figure 5-14. This percentage decreased exponentially 
with increasing numbers of therapy pulses (R2 = 0.97), and reached nearly zero shortly after 200 
pulses per treatment location. 
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Figure 5-14: Percentage of structurally intact cell nuclei decreased exponentially with increasing 
numbers of therapy pulses per treatment location. Dashed line: y = 99.37·e -0.01362·x (R2 = 0.97). 
Color Doppler velocity profiles were collected after each of up to 2000 therapy pulses at 
the center of the treated volume for the 15 ex vivo liver treatments. Figure 5-15 shows the 
average velocity profile over the three 2000 pulse treatment. The estimated velocity is shown in 
color (red is away from the therapy transducer and blue is towards the therapy transducer) versus 
the delay from the therapy pulse (y axis) and therapy dose (x axis). The Doppler velocity profiles 
in the ex vivo porcine liver were similar to the agarose phantom, with a brief period of chaotic 
motion followed by coherent push and rebound motions. These coherent motions also expanded 
in time with increased therapy dose up to 800 pulses, likely due to increasing fractionation 
leading to complete tissue liquefaction at 800 pulses. After that point, the push duration stayed 
roughly constant or decreased slightly with increasing number of therapy pulses. 
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Figure 5-15: Plot showing the average velocity estimates from Doppler after every therapy pulse 
in ex vivo porcine liver. The plot shows velocity (color map) versus time after the therapy pulse 
(y-axis) over the course of therapy (x-axis) (N=3). 
The tPRV metric was computed from the color Doppler data collected during the 2000 
pulse ex vivo liver treatments. This metric is plotted in Figure 5-16, showing a rapid increase in 
the tPRV metric for the first 200 pulses, corresponding to the rapid fractionation necessary to 
cause the extent of the damage observed histologically at this time point. The tPRV metric 
continued to slowly increase from 200 to 800 pulses, indicating continued fractionation of the 
tissue fragments. After approximately 800 pulses, no consistent change in the bubble induced 
motion following additional histotripsy therapy pulses was observed. The metric was computed 
for all 2000 therapy pulse, but is displayed with mean and standard deviation for only every 10th 
pulse for the first 200 pulses (Figure 5-16b), and every 40th pulse for the first 1200 pulses (Figure 
5-16b) for easy of visualization. From 1200 to 2000 pulses, tPRV has a flat trend, similar to that 
from 800-1200 pulses. 
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Figure 5-16: Plots of tPRV metric over the course of therapy in the ex vivo porcine liver tissue. 
Panel (a) shows the rapid increase in the tPRV metric during the first 200 pulses and panel (b) 
shows the slower increase from 200 to 800 pulses. Pulses beyond this point generated no 
significant change in the tPRV metric (N = 3). 
The correlation between the tPRV metric and the PNR metric was then computed to 
determine the validity of the tPRV metric to measure the degree of fractionation in tissue and is 
shown in Figure 5-17. This analysis was confined to the first 500 pulses, since the reference 
metric of fractionation progress (PNR) saturated at this point, providing no additional 
information about the fractionation progression for additional therapy. 
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Figure 5-17: PNR metric vs. tPRV metric for the first 500 pulses of therapy in the ex vivo liver 
samples. Dashed line: y = -9.107•x + 102.5 (R2 = 0.95) (N = 3). 
The FD-FMV metric was computed from the color Doppler data collected during the 
2000 pulse ex vivo liver treatments using at a delay of 14.3 ms. This metric can be visualized in 
the full velocity progression (Figure 5-10) as the velocity value (color axis) for each value of 
therapy dose (x-axis) at a fixed delay of 14.3 ms (y-axis). The pulse to pulse variation in the 
Doppler velocity measurement leads to increased noise in this measurement, for this reason, a 10 
point rolling average filter was applied to each individual FD-FMV vs dose trace before 
comparison. This metric is plotted in Figure 5-18a for the first 500 pulses with mean and 
standard deviation for every 25th pulse for clarity. This delay was chosen since it behaved 
similarly to the tPRV metric, capturing the rapid increase in the observed velocity for the first 200 
pulses, with a slower increase beyond 200 pulses. The correlation between the FD-FMV metric 
and the PNR metric was then computed to determine the validity of the metric to measure the 
degree of fractionation in tissue and is shown in Figure 5-18b. This analysis was also confined to 
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the first 500 pulses, due to the saturation of the reference metric of fractionation progress (PNR) 
at this point. A linear correlation was observed between the tPRV metric and the reference PNR 
metric (R2 = 0.95). 
 
Figure 5-18: Panel (a) shows the FD-FMV metric at 14.3 ms delay for the first 500 pulses of 
therapy in the ex vivo liver samples. Panel (b) shows the PNR metric vs. the FD-FMV metric for 
the first 500 pulses in the ex vivo liver samples. Dashed line: y = 310.7•x + 87.85 (R2 = 0.93) (N 
= 3). 
5.4 Discussion 
The imaging feedback method proposed in this paper relies on bubble-induced motion 
after each histotripsy pulse at the therapy focus along the axis of propagation. The source of this 
motion is not fully understood at this time, but the experiments presented here demonstrate that 
the phenomenon is consistent and reproducible. Several potential mechanisms have been 
identified, and are currently being investigated. Acoustic radiation force is a tempting choice for 
the mechanism behind the type of push-rebound motions observed in this study, however the 
extremely short pulses (< 2 cycles) are not sufficient to generate the observed motion simply 
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through absorption alone. Moreover, preliminary experiments show no measurable focal velocity 
at slightly sub-cavitation threshold pulses (~28.7 MPa peak negative pressure) with large 
velocities comparable to those observed in this study for supra-threshold pulses (~38.6 MPa peak 
negative pressure). This does not completely eliminate acoustic radiation force however, as the 
presence of forming cavitation bubbles could greatly enhance the radiation force via reflection of 
subsequent acoustic energy. The violent collapse of the histotripsy bubble cloud is another 
potential mechanism that could generate the observed motion. Certainly the cloud collapse 
generates much of the chaotic motion in the focal region observed in this study, but it could also 
generate consistent pushes of the focal region should the transducer geometry produce bubble 
clouds that consistently collapse asymmetrically. Another potential mechanism is asymmetric 
expansion of the bubbles during the formation of the bubble cloud. High speed imaging has 
shown that as the individual bubbles form, they grow more along the direction of propagation 
than back toward the therapy transducer, generating a net force on the medium. The cumulative 
effect of all the bubbles could generate the motion observed in this study. Some combination of 
these mechanisms is also possible, and a comprehensive study is in progress based on these 
preliminary results to fully elucidate the mechanism behind this observed motion. 
One advantage of the methods presented in this work is the ability to acquire these 
metrics during therapy, for real-time feedback on histotripsy fractionation progression. An 
important consideration is therefore how rapidly these metrics can be computed. The primary 
metric presented in this work, tPRV, has significant acquisition and computational requirements. 
The major computational element is the processing of the 190 color Doppler acquisition sets to 
form the full 20 ms velocity profile at the 0.1 ms time resolution used in this work. A real-time 
method using these exact techniques would likely achieve frame rates around 0.25 Hz, though 
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optimization and parallelization would likely improve this by a factor of 10. Therapy monitoring 
at this rate would be most useful for volume ablations similar to the 6 mm cube treatment 
presented in this work, where the treatment progression is monitored for a single location with 
the remainder of the lesion treated during processing. Once the monitored location has been 
sufficiently fractionated, additional probing pulses with color Doppler fractionation feedback 
could be directed to other points in the treated volume to verify complete treatment over the full 
lesion. If focal steering is not possible, or serial lesion creation is required, this feedback can still 
be acquired for some subset of the therapy pulses applied. For example, if therapy is applied at 
100 Hz PRF, and color Doppler feedback rate is possible at 1 Hz, you would pause therapy for 
the 20 ms Doppler acquisitions every 100th pulse, and process the data while treating another 100 
pulses at 100 Hz. However, it may be necessary in certain applications to gather feedback more 
rapidly, and for this reason the FD-FMV metric was developed. The FD-FMV metric is 
essentially a spatial velocity average taken from a standard color Doppler imaging sequence. 
This metric is currently achievable in real-time at an average rate of 30 Hz on the Verasonics 
imaging system used in this study. The only requirements are that the color Doppler acquisitions 
be synchronized and delayed from the therapy pulses by a predetermined amount, and that 
ultrasound imaging system provides access to the color Doppler data for spatial averaging. The 
required delay would be determined from preliminary tissue studies, similar to those presented 
here, in the target tissue to identify an appropriate delay that generates a metric sensitive to the 
desired therapeutic endpoint. Other metrics, extensions of these metrics, or detectors based on 
these metrics are also possible from bubble-induced color Doppler feedback including: push or 
rebound duration metrics, fixed delay peak velocity or zero-crossing detection, and focal mean 
velocity saturation detection. 
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 Other methods for quantitative histotripsy therapy feedback have been developed 
previously, including ultrasound backscatter reduction [1, 2], ultrasound shear wave elastography 
[13], and peak-to-peak displacement of the shear displacement profile [REF]. Though the results 
cannot be directly compared due to the use of a different transducer and therapy pulsing 
parameters, we are encouraged by the sensitivity of the elasticity metric for detecting histotripsy 
therapy progress at low therapy doses presented in [13]. We believe that changes to the tissue 
mechanical properties, especially elasticity, at the focus in response to histotripsy fractionation 
are the primary cause of the changes to the bubble-induced velocity profile captured by the 
metrics presented in this work. No direct calculations of tissue mechanical properties are possible 
using these methods at this time, since the mechanism of the push is not fully understood; 
therefore additional work is necessary to determine what tissue properties are being measured 
using these techniques.  
Although the methods presented here were only tested in liver tissue, the principle is 
likely applicable in other tissues that soften as they are increasingly fractionated by histotripsy 
pulses. Based on our experience, most soft tissues follow this trend, including liver [1], kidneys 
[15, 16], prostate [17-20], heart [21-23], and thrombus [24]. Although the different tissues begin 
therapy, and likely end therapy, with varying mechanical properties, it is expected that this 
softening will result in a temporally expanding velocity profile similar to that observed in liver in 
this work. Furthermore, we anticipate that metrics extracted from color Doppler measurements of 
the bubble-induced motion resulting from histotripsy therapy will change as the tissue is 
increasingly fractionated and eventually saturate when the tissue is completely homogenized. 
Therefore these metrics, or similar metrics from color Doppler acquisitions, are potentially useful 
for real-time feedback during any histotripsy therapy application. 
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5.5 Conclusion 
This chapter shows that histotripsy pulses generate a consistent push at the therapy focus. 
Characteristics of this push and rebound motion can be accurately estimated using standard color 
Doppler acquisitions due to enhanced scattering from the residual cavitation nuclei persisting 
after histotripsy bubble cloud collapse. This was verified by direct comparison with simultaneous 
optical PIV measurements of the motion of these nuclei in an otherwise acoustically transparent 
agarose gel phantom. The tissue response to this push changes significantly as the tissue is 
fractionated by histotripsy. This change can be quantified by metrics extracted from color 
Doppler acquisitions acquired during continuous therapy. These metrics are closely related to the 
degree of tissue fractionation as indicated by reference metrics of tissue damage (e.g. RBC lysing 
and percentage of the structurally intact cell nuclei), thereby providing real-time quantitative 
feedback on the fractionation progression. Further analysis, targeting a specific tissue and 
therapeutic endpoint, could refine these methods into a valuable feedback metric for any tissue 
that can be fractionated using histotripsy. 
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Chapter 6 
An Integrated Histotripsy Therapy System for Pediatric Cardiac Applications 
6.1 Introduction 
To transition histotripsy into a clinical tool for pediatric cardiac applications, an 
integrated, ultrasound image-guided, histotripsy therapy system should be designed and 
constructed specifically for the human neonate with congenital heart disease. This complete 
histotripsy therapy system includes an integrated probe; consisting of a compact therapy 
transducer, an acoustic coupling apparatus and an ultrasound imaging probe. The system also 
includes the control unit; consisting of the ultrasound imaging system, driving electronics for the 
therapy transducer, and a macro-positioning arm and motorized micro-positioner to connect and 
manipulate the integrated probe. The control unit should be a mobile cart and chassis, housing 
the ultrasound imaging system, the driving electronics and a host computer with software to 
control and integrate all the components (Figure 6-1). 
 107 
 
 
Figure 6-1: Block diagram of the complete, integrated pediatric cardiac histotripsy therapy 
system 
This chapter will focus first on development of materials and methods for therapy 
transducers for the pediatric cardiac application specifically. This includes the analysis of several 
piezo-electric materials for use in custom transducers, as well as the testing of various array 
designs including several transducers built in-house and a custom manufactured commercial 
transducer. Second, a custom ultrasound imaging probe will be designed to integrate directly into 
these transducers and minimize loss of active area in the therapy transducer design.  This probe 
will be built compatible with an ultrasound imaging system that allows flexible programing for 
the potential integration of custom guidance and therapy feedback techniques (e.g. color Doppler 
fractionation feedback, motion tracking, etc). Finally, a description of other required parts and 
integration of all components into a complete pediatric cardiac histotripsy system is detailed. 
 
6.2 Histotripsy Therapy Transducer 
The primary component of this integrated pediatric cardiac histotripsy therapy system is 
the histotripsy transducer. The main design consideration for this application is the acoustic 
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access to the heart in the human neonate. Echocardiography data collected from HLHS patients 
in previous work (Table 6-1) shows a subcostal acoustic window free of rib and lung obstruction 
with very little atrial septum motion [1]. 
Table 6-1: Measurements on Human HLHS Neonatal Patients using Echocardiography 
Measurements Coronal (mm) Sagittal (mm) 
Skin to RA wall distance 21.5 – 28.0 20.7-27.5 
RA wall to Atrial Septum 
distance 
11.2 – 18.5 11.4-17.5 
Atrial Septal thickness 1.7 –  2.2 1.5-2.1 
Atrial Septal Length 11.2-17.4 8.8-11.4 
Septum to LA wall distance 7.7 – 10.4 8.8- 11.4 
Septal motion 1 – 2 1-2 
RA free wall motion 1 – 3 1-3 
LA free wall motion 0 – 1 0-1 
 
Based on this data, the transducer must be capable of generating a histotripsy bubble cloud on 
the atrial septum in the neonatal heart through the roughly 4 x 6 cm subcostal acoustic window 
through an estimated 3-4.5 cm of overlying tissue in the acoustic path. Transducers were 
designed with slightly larger active area than this to ensure full utilization of the acoustic 
window. To accommodate differences in anatomy, the transducer must have at least 4.5 cm of 
working distance (perpendicular distance from the front plane of the transducer to the focal 
position), or be steerable along the propagation axis to allow for working distances of 3 – 4.5 cm.  
 Methods have been developed within our research group to design and manufacture 
therapy transducers of any geometry at low cost.  These transducers contain multiple flat 
piezoelectric elements acoustically matched to a focusing lens within a custom housing shell 
designed in 3D modeling software and manufactured using stereolithography (SLA) rapid 
prototyping. There are four main advantages of using this rapid prototyping method to build a 
high pressure, focused transducer in comparison to using a single segment of spherical 
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piezoelectric crystal: 1) the cost and time to develop and build a transducer is significantly 
reduced, as small flat piezoelectric elements are readily available, 2) transducers can be easily 
built for any complex geometry, 3) acoustic matching layer can be applied to increase the 
transducer bandwidth and surface pressure transmission to the media, and 4) the electric 
impedance of the smaller element allows (through our amplifier) very high voltage to be 
delivered and high pressure to be achieved. These methods are ideal for rapid iteration in early 
feasibility testing; however, a custom manufactured transducer has several main advantages that 
make it more suitable for a clinical prototype.  The primary advantage is that the array elements 
can be arbitrarily shaped and sized, allowing for elements to be much more densely packed and 
even arranged to allow steering of the therapy focus. Secondarily, since the goal of this work is 
develop a tool to translate histotripsy into a clinical trial, a device manufactured within 
regulatory guidelines, using materials certified for bio-compatibility would expedite this process. 
Based on the strengths of these methods; initial prototype design, manufacture, and testing would 
be conducted in house to determine an optimal design for a final prototype to be manufactured 
by a third party with electrical and biocompatibility certification included.  
 
6.2.1 PZT-4 and PMN-PT Single Crystal Element Testing 
Previous transducers built within our group have primarily used lead zirconium titanate 
(PZT), or more specifically the PZT-4 composition. A single crystal PMN-PT material (JFE 
Mineral Company LTD., Tokyo, Japan) is assessed here for potential use in the pediatric cardiac 
transducer to increase the pressure output versus this standard. The PZT-4 elements used were 
diced from 45mm plates of SM111, a modified formulation of PZT-4 (SMPL45W45T14111, 
Steiner and Martin Inc., Miami, USA). To directly compare the PMN-PT single crystal with a 
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standard PZT-4 transducer, single element housings with acoustic focusing lens and ¼ 
wavelength tungsten epoxy matching layer were designed and constructed. Identical housings 
were manufactured using SLA rapid prototyping and assembled with a single crystal PMN-PT 
element (20 x 20 x 1.5 mm) and a PZT-4 element cut to the same size. Though these elements 
are manufactured for use at 1.5 MHz, they were electrically matched and driven at 1.25 MHz. 
This is possible due to the increased bandwidth that results from acoustically matching the 
element to the lens with a tungsten epoxy layer. To facilitate maximum electrical driving 
efficiency, the elements were electrically matched using an “L-C” type matching network. The 
PMN-PT element started with an electrical impedance of 40.7 – j12.6 ohms, and was electrically 
matched to 5.4 ohms. The PZT-4 element started with an electrical impedance of 12.4 – j44.2 
ohms, and was matched to 7 ohms. This resulted in voltage gains of about 4 for the PMN-PT 
element and 5.4 for the PZT-4 element. 
 The transducers were driven with high-voltage square waves at 1.266 MHz, and the 
pressure output was measured using a 200 µm piezoelectric “bullet” hydrophone (HGL-0200; 
Onda Corp., Sunnyvale, CA) for 2D planes perpendicular to the propagation direction 6 mm 
from the element surface and at the geometric focus. The driving voltage used in each case 
resulted in 150 V peak to peak (Vpp) applied to the element in all tests. The 2D surface pressure 
profiles for the PZT-4 and PMN-PT transducers are shown in Figure 6-2. The PZT-4 produced a 
mean peak negative pressure of about 120 kPa over the 20 x 20 mm scan, while the PMN-PT 
produced a mean peak negative pressure of 275 kPa. The notch of reduced pressure on the right 
side of both profiles corresponds to the hollow well in the lens where the front electrode attaches 
to the element. 
 111 
 
 
Figure 6-2: Surface pressure measurements taken ~6 mm from the transducer elements for the 
PZT-4 transducer (left) and the PMN-PT transducer (right). 
 2D focal pressure profile for the PZT-4 and PMN-PT transducers are shown in Figure 6-3. 
The PZT-4 produced a peak negative pressure of 0.69 MPa, while the PMN-PT produced a peak 
negative pressure of 1.9 MPa. The PMN-PT element focused more sharply, despite the identical 
element size, housing and lens (-6 dB beam width of 2.72 mm for the PMN-PT versus 3.18 mm 
for the PZT-4). 
 
Figure 6-3: Focal pressure scans taken at the geometric focus of the lens ~ 65 mm from the 
transducer elements for the PZT-4 transducer (left) and the PMN-PT transducer (right). 
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 To assess the performance at higher driving voltages (up to 1578 Vpp for the PMN-PT 
element, and 1781 Vpp for the PZT-4 element), pressure measurements were taken using a fiber 
optic hydrophone [2] at a single point near the surface and at the geometric focus. An example 
focal pressure waveform for the two transducers driven with the same peak to peak driving 
voltage (525 Vpp) is shown in Figure 6-4. In this case, the PZT-4 element produced a peak 
negative pressure of 2.5 MPa and the PMN-PT element produced a peak negative pressure of 3.4 
MPa. These waveforms show well developed shock fronts impinging on the negative half cycles, 
indicating that acoustic saturation could be an issue for higher driving voltages, especially for the 
PMN-PT element. 
 
Figure 6-4: Pressure waveforms for the PZT-4 element (left) and PMN-PT element (right) when 
driven with 525 Vpp on the element. 
 Surface pressure and focal pressure versus driving voltage are shown in Figure 6-5. The 
PMN-PT transducer was able to generate nearly 7 MPa of surface pressure, versus roughly 3.8 
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MPa from the PZT-4 transducer. At this focal length and frequency however, the difference in 
focal pressure was not as drastic due to the effects of non-linear propagation. Focal pressure 
saturated at around 7.5 MPa for the PMN-PT with the PZT-4 element saturating around 5.2 MPa, 
for an improvement of around 44%. 
 
Figure 6-5: Peak negative pressure versus applied voltage for both transducers measured at the 
surface (left) and at the focus (right). 
6.2.2 PZ36 Element Testing 
 A low impedance formulation of PZT (PZ36, Meggitt, Kvistgaard, Denmark) was tested 
for its potential use in histotripsy therapy transducers similarly to the previous section. The PZ36 
elements were ordered in a 15 mm square size to facilitate better packing density in array designs, 
and therefore could not be directly compared to the previous set of experiments. A single 
element housing similar to those used in the PMN-PT testing was designed and constructed, with 
the only notable difference being the removal of the ¼ wavelength tungsten-epoxy matching 
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layer. The matching layer was not necessary due to the low acoustic impedance of the PZ36 
material, allowing direct coupling to the lens material. These PZ36 elements started with an 
electrical impedance of 27 – j30.2 ohms and were electrically matched to about 10.4 ohms 
resulting in a voltage gain of about 3.2. Surface and focal pressure profile measurements were 
taken using a 500 micron “needle” hydrophone (HGL-0500; Onda Corp., Sunnyvale, CA) over a 
15mm x 15mm region at the surface with the transducer driven with 656 Vpp and a 6mm x 6mm 
region at the focus when driven at 344 Vpp. Both scans were taken with 500µm separation 
between grid points. The 2D surface pressure profile for the PZ36 transducer is shown in Figure 
6-6. The PZ36 produced a mean peak negative pressure of about 1.9 MPa over the 15 x 15 mm 
scan. The increasing pressure trend from top right to bottom left is likely the result of the 
transducer element not being entirely parallel to the scanned plane. This misalignment results in 
the hydrophone being closer to the transducer for some measurements. 
 
Figure 6-6: Surface pressure measurements taken ~5 mm from the transducer element for the 
PZ36 transducer driven with 656 Vpp. 
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 Peak pressure measurements at the transducer focus were taken using the fiber optic 
hydrophone for peak to peak voltages on the element from 344 volts to 950 volts to determine 
the maximum pressure output. An example focal pressure waveform for the PZ36 transducer 
driven with a peak to peak driving voltage of 569 V is shown on the left in Figure 6-7. In this 
case, the PZ36 element produced a peak negative pressure of 2.7 MPa. Peak negative pressure 
versus driving voltage is shown on the right in Figure 6-7. The sample lost power output at 
driving voltages higher than 1000 Vpp, and was confirmed by comparison of the impedance 
before and after testing to have been irreparably damaged. 
  
Figure 6-7: Peak negative pressure output of the 15 mm PZ36 element. An example pressure 
waveform (left) when driven with 569 Vpp on the element, along with the peak negative pressure 
versus driving voltage (right). 
6.2.3 5 Element Array Design and Testing 
 An initial prototype transducer was designed and manufactured in house. This design 
(Figure 6-8 left) consists of five 2.25 cm square PZT-4 elements with acoustic matching and lens’ 
aligned confocally, each with a 6.5 cm focal length. The elements were cut from the same 45mm 
plates described in the previous section. The working distance of the five element array is 4.5 cm, 
0 2 4 6 8 10
-2
0
2
4
6
8
Time (sec)
P
re
ss
ur
e 
(M
P
a)
400 600 800 1000
1.5
2
2.5
3
3.5
4
Driving Voltage (V)
P
- P
re
ss
ur
e 
(M
P
a)
 116 
 
the maximum housing dimensions are 6.5 x 8.5 cm, and the active aperture is about 5.1 x 7.1 cm. 
This design has an approximate 40% utilization of the transducer footprint (total element area 
divided by the area of the housing’s footprint), and a 70% packing density (total element area 
divided by the usable front face area). A 12 MHz phased array imaging probe provision is 
aligned with the therapy focus lying on the imaging axis (Phillips S12) for therapy guidance 
using an available ultrasound imaging system. The focal widths of this 1.25MHz therapy 
transducer (-3dB from the peak pressure) are simulated to be 1.07 (lateral) x 1.83 mm 
(elevational) x 8.01 mm (axial) (Figure 6-8 right).  
 
Figure 6-8: (Left) Rendering of the initial prototype transducer, with 5 piezo-ceramic transducer 
elements (dark gray) confocally aligned and a 12 MHz ultrasound imager aligned with the 
therapy focus along the imaging axis. (Right) 2D simulated focal gain pressure profiles for this 
configuration 
The 5 elements were electrically matched to around 12 ohms impedance at 1.25 MHz, 
generating a voltage gain of approximately 3.5 and driven with a custom five-channel class D 
amplifier. The focal beam profile was measured using a “bullet” hydrophone with an 85 micron 
tip (HNR-0085, Onda Corp., Sunnyvale, CA). The measured focal beam profiles were slightly 
larger than those predicted by simulation, measuring roughly 1.31 mm (lateral) x 1.97 mm 
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(elevational) x ~9.5 mm (axial, extrapolated). This is likely explained by the wider focal zone of 
the PZT-4 elements that was observed in the single element testing in section 6.2.1. 
 
Figure 6-9: Normalized pressure profiles of the main lobe at the geometric focus for the 5 
element transducer. 
The maximum pressure output measured using a fiber optic hydrophone for voltages 
between 70 and 1050 Vpp. The transducer was able to achieve maximum pressure output when 
driven with 6 cycles from a five-channel class D amplifier, generating peak negative pressures 
up to 22 MPa (Figure 6-10) as measured with a fiber optic hydrophone. The pressure output 
appeared to saturate at this point, likely due to non-linear propagation of the large peak positive 
shockwave impinging on the negative half-cycle. This is consistent with the single element 
testing, where the pressure appeared to saturate around 5 MPa at the focus of a single element. 
That element was slightly smaller than the elements used here, and therefore required higher 
voltage to achieve that pressure. For this reason, even though the elements could be driven up to 
1400 VPP, increased focal pressure was not observed for applied voltages over 820 V peak to 
peak in water. The ability to apply higher voltages is however necessary in the case of 
attenuating media, where increased surface pressure will be necessary to achieve similar focal 
pressures. 
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Figure 6-10: Focal Pressure for the 14 element transducer measured at 820 Vpp (left) with the 
peak negative pressure versus applied voltage (right) all measured using a fiber optic hydrophone. 
This design was then evaluated for use in the ongoing feasibility studies for histotripsy in 
pediatric cardiac applications. The transducer was fired through 2.5 cm of porcine ribcage and 
muscle tissue in vitro, were it was demonstrated to be capable of sustaining a bubble cloud 
through 2.5 cm of porcine ribcage and muscle tissue in vitro, performing comparably to the 1 
MHz annular array transducer used for the in vivo neonatal porcine ventricular septal defect 
creation studies in Chapter 2. An in vivo study targeted the ventricular septum, mirroring the 
procedures outlined in Chapter 2 with this new transducer replacing the larger 9 cm aperture 1 
MHz transducer used for that work. In this study, the transducer provided 4 separate treatments 
totaling 7.5 minutes of therapy on the ventricular septum, after which the presence of a newly 
created VSD was confirmed by color-flow Doppler observation of a flow channel between the 
ventricles. 
A second in vivo experiment used the same setup, only targeting the atrial septum for 
defect creation. In this case, the transducer could not reliably generate a cavitation cloud on the 
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atrial septum, suggesting the need for a more powerful transducer. Having the imaging 
transducer off the therapy axis proved to be sub-optimal in these in vivo studies as well, as in 
certain cases cavitation was audible but could not be visualized on ultrasound imaging. This was 
likely due to the cloud forming slightly in front of or behind the geometric focus, which is 
outside the imaging field for all imager rotational orientations besides aligned with the axial-
elevational plane of the therapy transducer. 
6.2.4 14 Element Array Design 
 A second prototype was designed and manufactured using smaller elements to facilitate 
denser element packing for increased active area. The use of more, lower pressure elements that 
interact only very near the transducer focus should reduce the nonlinear acoustic saturation 
effects as well. This transducer (Figure 6-11) consists of fourteen 1.5 cm square elements cut 
from the same 4.5 cm PZT-4 plates as the previous transducer with acoustic matching and lens’ 
aligned confocally, each with a 6.5 cm focal length. The working distance of the fourteen 
element array is 4.5 cm and the maximum housing dimensions are 6.2 x 9.0 cm. In this case, the 
12 MHz phased array imaging probe provision is centered in the therapy transducer, with the 
imaging axis aligned with the therapy axis. This design has an approximate 49% utilization of 
the transducer footprint with active area and a 73.3% packing density. This is a slight 
improvement in packing density over the previous design, but more importantly, an increase of 
over 600 mm2 of active area.  
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Figure 6-11: Rendering of the second prototype transducer with 14 piezo-ceramic transducer 
elements confocally aligned and a 12 MHz ultrasound imager aligned directly with the therapy 
axis. 
The 14 elements were electrically matched to around 5 ohms impedance at 1.25 MHz, 
resulting in a voltage gain of around 5.2. This increased the potential peak to peak voltage that 
could be applied to the elements to around 2000 V. The focal beam profile was measured using 
the same 85 micron “bullet” hydrophone, and was very similar to the 5 element transducer due to 
their similar shape and identical frequency and focal length. The focal widths measure roughly 
1.23 mm (lateral) x 1.82 mm (elevational) x ~9.5 mm (axial, extrapolated). The 2D 
lateral/elevational beam pattern at the axial focus is shown on the left in Figure 6-12 along with 
1D profiles in the 3 principle axes. All measurements where done with the “bullet” hydrophone. 
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Figure 6-12: 2D beam profile of normalized peak negative pressure around the geometric focus 
of the 14 element transducer. 
The maximum pressure output was estimated by summing measurements of the output of 4 
groups of elements using a fiber optic hydrophone. The 14 elements were divided into 4 groups 
of 3-4 elements. The 3 middle elements on the top and bottom made up the first 2 groups, and 
the remaining 4 elements on each side made up the other 2. Groups were composed of adjacent 
elements to preserve as much of the impact of non-linear interaction between elements as 
possible. This transducer was able to achieve maximum pressure output when driven with 5 
cycles from a fourteen-channel class D amplifier, generating estimated peak negative pressures 
up to 32 MPa. Pressure waveforms with all elements firing could only be taken up to 910 Vpp, 
where the transducer generated about 21.5 MPa peak negative pressure (left of Figure 6-13), as 
higher negative pressures generated cavitation on the hydrophone’s fiber tip that corrupted the 
measurements. Estimated pressure from summing the output of 4 groups of elements agreed well 
with direct measurements up to this point (right of Figure 6-13). Additional non-linear 
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propagation losses are likely with all elements firing however, and the actual pressure output is 
likely lower than these estimates at very high driving voltages. 
 
Figure 6-13: Focal Pressure for the 14 element transducer measured directly at 910 V (left) with 
a comparison of the peak negative pressure measured directly vs the extrapolation from summing 
the output of 4 subgroups of elements (right) all measured using a fiber optic hydrophone. 
This design was also evaluated for use in the ongoing feasibility studies for histotripsy in 
pediatric cardiac applications. The transducer was used in a series of in vivo validation 
experiments targeting the atrial septum in a neonatal porcine model with various augmentations 
to reduce pre-focal lung obstruction. In these studies, the transducer was often able to generate a 
cavitation cloud on the atrial septum, however sufficient treatment time to generate an ASD was 
not possible secondary to deteriorating lung function. This was likely due to increased overlying 
lung tissue in the pre-focal acoustic field when targeting the atrial septum versus targeting the 
ventricular septum. Augmentations to the model to remove pre-focal lung obstruction improved 
treatment times, but could not completely prevent lung damage. 
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6.2.5 19 Element Transducer Design 
 A final prototype transducer was designed in cooperation with a transducer 
manufacturing company (Imasonic, S.A., Besançon, France). Professional manufacturing was 
utilized since their fabrication techniques allow for arbitrarily shaped and sized elements, 
facilitating both increased element packing density and steerable array designs. A limitation of 
fixed focus designs is that they must be designed to accommodate the maximum possible 
working distance, and therefore are most often used with a significant standoff from the patient 
when targeting individuals with a shallower target depth. This standoff reduces ultrasound image 
quality and therapy focal gain. A steerable design is optimal, such that the therapy probe can 
always be positioned against the skin, and the focal location steered to the target depth. For this 
reason, the prototype transducer was designed with the elements arranged within 6 concentric 
rings, allowing focal steering along the therapy axis. These rings were divided into equal area 
sections to allow for easy and consistent electrical matching and amplifier integration. The rings 
were also truncated to match the roughly rectangular acoustic window in the human neonate 
Figure 6-14. The transducer was designed with a 60 mm focal length, since this resulted in the 
highest focal gain over the estimated anatomical range of working distances. The simulations of 
the pressure field and steered focal gain are shown in Figure 6-15. 
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Figure 6-14: Diagram of the axis-steerable therapy array design. 19 elements of equal area are 
arranged into 6 concentric rings. The aperture is truncated into a 5 x 7 cm rectangle with a 2.6 
cm diameter center hole for the ultrasound imaging transducer. 
 
Figure 6-15: Simulation results for this 19 element, 1 MHz array transducer showing the pressure 
field (left) along with the steered pressure gain for steered focal lengths of 50, 55, and 60 mm. 
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 The transducer housing was designed to minimize the lateral dimensions, and resulted in 
a housing of 6.2 x 7.6 cm. This design has 19 elements of 155 mm2 (2945 mm2 total), resulting 
in a 64% utilization of the transducer footprint with active area and a 90% packing density. The 
housing included a center hole provision for a ultrasound imaging transducer that will be detailed 
later in this chapter.  
The transducer was manufactured and delivered by Imasonic, and configured for testing 
with a 19 channel class D amplifier system. The element impedance was measured to be 120±3.4 
ohms real part, and -234±4.5 ohms imaginary part. The elements were matched to approximately 
22 ohms using an “L-C” matching network, resulting in a voltage gain of about 3.5. The focal 
beam profile was measured using a 500 micron “needle” hydrophone (HNR-0500, Onda Corp., 
Sunnyvale, CA). The beam profile for the 19 element array transducer was again very similar to 
the previous transducers due to their similar shape. In this case however, a lower frequency (1 
MHz here vs 1.25 MHz previously) and smaller aperture (5 x 7 cm with this design versus 8.1 x 
5.3 cm of the 14 element array) resulted in the focal zone being slightly larger. The focal widths 
measure roughly 1.51 mm (lateral) x 2.17 mm (elevational) x 9.9 mm (axial). The 2D 
lateral/elevational beam pattern at the axial focus is shown on the left in Figure 6-16 along with 
1D profiles in the 3 principle axes. All measurements where done with the “needle” hydrophone. 
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Figure 6-16: Normalized 2D peak negative pressure profile in the lateral/elevational planes at the 
axial focus (left), along with 1D scans on the principle axes (right) as measured with the “needle” 
hydrophone. 
Maximum pressure output was estimated by summing measurements of the output from 2 
groups of the elements using a fiber optic hydrophone. These two groups were composed of the 
two halves of the transducer, split along the axial/elevational plane, resulting in groups of 10 and 
9 elements. The extra element in one group results from the ring that is split into 3 elements, as 
opposed to the others rings that are split into 2 or 4 elements (Figure 6-14). This transducer was 
able to achieve maximum pressure output when driven with 3 cycles from a nineteen-channel 
class D amplifier, generating estimated peak negative pressures up to 40 MPa. Pressure 
waveforms with all elements firing could only be taken up to 588 Vpp, where the transducer 
generated about 24 MPa peak negative pressure (left of Figure 6-17). Estimated pressure from 
summing the output of 2 groups of elements agreed well with direct measurements up to this 
point (right of Figure 6-17). Summing the acoustic output from only 2 groups of elements should 
Lateral Position (mm)
E
le
va
tio
na
l P
os
iti
on
 (m
m
)
 
 
-2 -1 0 1 2
-3
-2
-1
0
1
2
3
N
or
m
al
iz
ed
 P
re
ss
ur
e
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
-2 -1 0 1 2
0
0.5
1
Lateral Position (mm)
-2 -1 0 1 2
0
0.5
1
Elevational Position (mm)
o
a
ed
es
su
e
-10 -5 0 5 10
0
0.5
1
Axial Position (mm)
 127 
 
maintain most of the effects of non-linear propagation in this case; however, additional losses are 
possible with all elements firing. For this reason, the actual pressure output is likely close, or 
slightly lower than these estimates at very high driving voltages. 
 
Figure 6-17: Focal Pressure for the 19 element transducer measured directly at 588 Vpp (left) 
with a comparison of the peak negative pressure measured directly vs the extrapolation from 
summing the output of 2 subgroups of elements (right) all measured using a fiber optic 
hydrophone. 
This design of the transducer and water box resulted in a working distance of 36.25 mm, 
and the HLHS application requires working distances between 30 and 45 mm. This would 
require a minimum steered focal length of 53.75 mm, and a maximum steered focal length of 
68.75 for this transducer. To assess the impact of steering on pressure output, the transducer was 
steered over 5 points within this range at identical driving voltages of 319 Vpp and focal pressure 
waveforms were acquired using the fiber optic hydrophone and compared to the pressure output 
at the geometric focus. The peak negative pressure over the required steering range is plotted in 
Figure 6-18, relative to the pressure achieved at the geometric focus. Focal pressure varied over 
the steering range from 81% to 108% of the peak negative pressure at the geometric focus. 
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Figure 6-18: Peak negative pressure over the required steering range relative to the geometric 
focus, showing a relative gain between 0.81 and 1.08 over the entire range.  
6.3 Integrated Histotripsy Therapy Cart  
6.3.1 Ultrasound Imaging System 
 Ultrasound is the imaging modality most often used to visualize structures and blood 
flow in the neonatal heart. Ultrasound imaging is inexpensive, fast, and flexible. The ultrasound 
imaging for this system must be able to accept synchronization from an external source since 
imaging during therapy will be required for therapy monitoring. This synchronization will 
eliminate interference from the high intensity histotripsy therapy pulses, increasing ultrasound 
image quality for therapy monitoring. Histotripsy therapy will be applied at a pulsing rate 
determined by safety and efficacy analysis, so the imaging sequence must be flexible enough to 
acquire between therapy pulses at a broad range of repetition rates. Custom image sequence 
modification will also be necessary to allow for the potential addition of imaging, guidance and 
feedback optimizations for this specific application that would not be possible with an “off the 
shelf” clinical ultrasound imaging system, including those developed in this work (Chapter 4, 
Chapter 5). 
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The Ultrasonix SonixTouch system is available in a research configuration, allowing 
arbitrary acquisition of frames or scan lines, custom probe compatibility, and full image 
sequence customization. This system has been used successfully previously by Histosonics Inc. 
in an integrated histotripsy therapy system for ultrasound image guidance and targeting in 
treating benign prostate hyperplasia (BPH). 
 To limit the loss of active area in the therapy transducer, a small imaging probe is 
essential. The ultrasound imaging probe must be capable of imaging structures and blood flow in 
the neonatal heart through the subcostal acoustic window with the estimated 3-4.5 cm of 
overlying tissue in the acoustic path. Clinically, a high frequency (> 5 MHz) phased array probe 
would be used for this scenario. The probe must be compatible with the chosen imaging system, 
and ideally, the probe housing would have a cylindrical shape to allow easy translation and 
rotation within a cylindrical hole in the therapy transducer. 
A custom phased array imaging probe was ordered from Vermon SA. The 64 element 
probe would have a center frequency of 4.9 MHz and 4 MHz bandwidth. This was the highest 
center frequency that their manufacturing techniques allowed. The probe was designed with a 20 
mm cylindrical housing, 64.2 mm long with a 2 m cable to an Ultrasonix connector Figure 6-19 
shows a detailed drawing of the probe design. 
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Figure 6-19: Detailed drawing of the custom image transducer, a 4.9 MHz phased array with 4 
MHz bandwidth. 
The custom PA7-4 imaging transducer was integrated into the Ultrasonix SonixTouch 
system, and a basic imaging study performed on an adult volunteer. Figure 6-20 shows an image 
of the custom built transducer on the left and a sample ultrasound image of the carotid artery of 
an adult volunteer taken with the transducer on the right. 
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Figure 6-20: Image of the custom PA7-4 transducer (left) along with an example image taken 
with the transducer of the carotid artery of an adult volunteer. 
6.3.2 Ultrasound Coupling Device 
To ensure efficient transfer of acoustic energy from the therapy and imaging transducers 
into the patient, a water box coupling system was designed. This water box coupler design 
simply extends the transducer housing evenly beyond the curved transducer face to form a flat 
front surface. This device was designed to preserve as much of the original working distance of 
the transducer as possible, though a loss of 2.7 mm of working distance was required. A thin 
flexible membrane will be affixed over the front opening to couple directly to the patient’s skin 
via ultrasound gel. A thin imager sheath with 3 rubber “o-rings” will be sealed to the imaging 
transducer so the cavity between the transducer and the front face of the coupling box can be 
filled with water for coupling. Figure 6-21 shows the detailed design drawings of the housing, 
imager sheath and water box. 
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Figure 6-21: Detailed drawing of the 1 MHz, 19 element array transducer design. The main 
housing measures 6.2 x 7.6 cm (not counting the 2-4 mm mounting shoulder for the coupling 
box). 
With the imager sheath, the ultrasound imager can be rotated or extended freely in the 
center hole of the therapy transducer, while maintaining a water-tight seal between the imager 
and therapy transducer. Figure 6-22 shows the imager sheath along with the imager mounted in 
the therapy transducer with the water box coupler attached. When telescoping, the inner volume 
of the water box will change. The small tube on the top and bottom of the water box are for 
connections to a water reservoir to allow flow in and out of the cavity during telescoping to 
allow this without affecting the coupling to the patient. Positive water pressure on these ports 
may also be useful to expand the front membrane and improve coupling to uneven surfaces. 
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Figure 6-22: Ultrasound imaging transducer with sheath (A) with rubber “o-rings” to form a 
watertight seal with the therapy transducer while maintaining the ability to telescope from a 
retracted position during therapy (B) to an extended position in direct contact with the patient’s 
skin (C) for better image quality during pre- and post-treatment imaging studies. 
6.3.3 Therapy Generator and Controller 
 The therapy transducer requires a multi-channel, high power amplifier to generate the 
high amplitude acoustic pulses necessary for histotripsy therapy. An amplifier for this 
application should allow a configurable number of channels, independent phasing of at least a 
subset of those channels, and should be able to produce a synchronization output appropriate for 
the imaging system. This amplifier must be able to generate high voltage (>1500 V peak to peak) 
and handle high instantaneous current (>30 A) on all channels to ensure that the therapy 
transducer can be driven to its maximum pressure output. Therapy will be applied at low duty 
cycles (< 1%) so time average power and thermal concerns should be minimal. The controller 
should allow a maximum center frequency of at least 1.5 MHz, a maximum of at least 10 cycles 
per burst, and at least 1000 Hz maximum burst repetition rate. Ideally, the therapy generator 
would also be built within the relevant electrical safety requirements for easier transition to 
clinical research. 
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 A custom histotripsy generator and controller meeting these requirements has been 
developed previously by Histosonics Inc. and integrated into an expanded chassis Ultrasonix 
SonixTouch system. The therapy generator can provide up to 1700 V peak to peak on up to 36 
channels up to 250W total power. The histotripsy control software, called Histotripsy Service 
Tool, is installed directly into the Ultrasonix host computer and supports main frequencies 
between 500 kHz and 3 MHz, 1 to 100 cycles per burst, and a burst repetition rates between 1 Hz 
and 100 kHz. The 36 total channels are divided among 6 boards, and each of these boards can 
have independent phasing set by the histotripsy controller. This system was chosen as the 
foundation for the integrated therapy system described in this chapter. 
6.3.4 Transducer Mounting and Positioning 
 A positioning system is required to mount the integrated therapy unit to the mobile 
chassis. The positioning arm should include some means to coarsely position the therapy unit 
over the patient’s abdomen, and a motorized fine positioning mechanism to accurately place the 
therapy probe focus on target. The positioning arm will need to support both the weight of the 
micro-positioning system and the estimated maximum 5 lb weight of the integrated therapy unit. 
The micro-positioning system should be able to translate the therapy unit at least 5 cm in 3 
orthogonal dimensions, with a minimum positioning accuracy of 100 microns. One axis should 
be aligned with the therapy/imaging axis. This will allow direct mechanical adjustment along the 
steering axis, and make positioning more intuitive for the operator based on the ultrasound 
imaging feedback. The mechanical micro-positioner should include joystick control, along with 
direct positioning commands through a console on the host computer. These positioning 
commands should include commands to move each axis, read the position of each axis, and store 
and easily return to a “home” position. 
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 A positioning arm meeting the requirements for the macro-positioning arm comes 
integrated into the expanded chassis Ultrasonix SonixTouch system chosen previously. A micro-
positioner was developed matching our requirements to mount directly to this positioning arm. 
The final stage would include a direct mount for the 19 element array transducer developed in 
the previous section. 
The completed integrated therapy probe was then mounted to the last stage of the 3 axis 
micro-positioner. This assembly was mounted to macro-positioning arm of the extended chassis 
therapy cart and is shown in Figure 6-23. With the water-tight front membrane attached to the 
water box, the integrated probe can be coupled directly to the patient’s skin via ultrasound gel. 
This completed the assembly of the integrated histotripsy therapy system for pediatric cardiac 
applications, and the final device is shown in Figure 6-24. 
 
Figure 6-23: Complete integrated probe mounted to the 3 axis micro-positioner at the end of the 
macro-positioning arm. 
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Figure 6-24: Completed integrated histotripsy therapy system. The integrated probe (A) includes 
the therapy transducer, coaxial imaging transducer and ultrasound coupling water box. The probe 
is mounted directly to the motorized micro-positioner (B) and manipulated by joystick (C) or 
direct commands through the console (D). Rough positioning of the probe and micro-positioner 
is accomplished by the manual positioning arm which is rigidly mounted to the cart chassis (G). 
This extended chassis (G) houses the therapy amplifiers and power supply, along with ultrasound 
imaging system (F), which is controlled through the touch panel (E) with images displayed on 
the main console (D). 
6.4 Discussion 
In this chapter several materials were tested for their potential in replacing PZT-4 for use 
in custom manufacturing of transducers in house. The PMN-PT single crystal consistently 
produced over twice the surface pressure of the comparably sized PZT-4 element at the same 
driving voltage, peaking at nearly 7 MPa of surface pressure. However, this increased output also 
led to increased acoustic saturation effects from nonlinear propagation. Surface pressures near 7 
MPa only resulted in focal pressures of less than 8 MPa for this focal length, despite the linear 
focusing gain of around 5 from the acoustic lens. This could potentially lead to significant 
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prefocal heating for these elements. These elements are much more expensive than PZT elements, 
costing several hundred dollars each versus the 5-20 dollars per element that PZT elements 
typically cost. These elements are also difficult to manufacture in this frequency range and below, 
due to fact that a single crystal must be grown to the full thickness. Based on these factors, these 
elements were not ideal for a transducer for this application, but should be considered for 
applications that require miniaturized, high frequency, short focal length histotripsy transducers 
in the future. 
Also of note from the PMN-PT material test was the increased focusing achieved versus 
the PZT-4 samples, despite the identical size, driving frequency, and acoustic lens (-6 dB beam 
width of 2.72 mm for the PMN-PT versus 3.18 mm for the PZT-4). A possible explanation can 
be formed based on the surface pressure profiles (Figure 6-2), where the PMN-PT produced a 
very even pressure field out to the edges, while the PZT-4 had reduced output near the edges. 
This made the radiating surface of the PZT-4 element smaller, effectively increasing the f-
number of that transducer. This could also contribute to the increased focal spot size that was 
observed for the 5 element array versus that predicted by simulation. 
The PZ36 material performed favorably in these tests, though no direct comparison was 
made with identical PZT-4 transducers. A single 15 mm square element at a 6.5 cm focal length 
(approximate f number of 3.8) was able to achieve over 4 MPa focal pressure. The major 
drawback was that this material proved significantly less resilient to high voltages than PZT-4, 
though its increased efficiency at lower applied voltages made up for that fact. An additional 
advantage of these elements is their low acoustic impedance, eliminating the need for an acoustic 
matching layer, reducing complexity in the printed housing and decreasing the difficulty in 
transducer assembly. It is for this reason that these elements have become a popular choice for 
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recent transducers, including an as-yet untested replacement for the 14-element array presented 
in this work. 
It was hypothesized that reduced focal pressure when targeting the atrial septum in the in 
vivo porcine model was the result of either increased attenuation, or blockage of the acoustic 
field. This motivated the development of the 14 element transducer, to increase the packing 
density and active area and increase focal pressure compared to the 5 element transducer. This 
transducer proved more capable of creating and maintaining a bubble cloud on the atrial septum, 
however cumulative damage to overlying pre-focal and post focal lung tissue limited treatment 
times. Augmentations to the model to remove pre-focal lung tissue improved treatment times, 
but damage to post-focal lung tissue still resulted in poor treatment outcomes. This is a limitation 
of the neonatal porcine model however, and does not imply the same challenges will be present 
in a human. Heart orientation differences between bipedal humans and quadrupedal pigs result in 
different therapy access to treat the atrial septum. In humans, therapy will be applied from the 
subcostal acoustic window, which is free of ribs and lung. For this reason the usefulness of this 
model may be limited, and alternatives should be pursued. 
 
6.5 Conclusion 
An integrated, ultrasound image-guided, histotripsy therapy system was designed and 
constructed. This system includes a histotripsy therapy transducer specifically designed for the 
human neonate with congenital heart disease. The system is a necessary tool for the experiments 
to establish feasibility of histotripsy for pediatric cardiac applications. With it complete, the next 
steps toward a clinical trial for histotripsy cardiac therapy in infants can be taken. 
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Chapter 7 
Summary and Future Work 
7.1 Summary 
This dissertation demonstrates the safety and effectiveness of cardiac histotripsy in a live 
animal model. Therapeutic creation of cardiac septal defects in necessary for the palliation of 
several forms of congenital heart disease and is typically performed invasively with surgical or 
cardiac catheterization techniques.   Nine VSDs were created in 9 intact neonatal pigs with 
minimal collateral damage or systemic side-effects. VSD size was variable (2-6.5 mm),  likely 
related to varying aberration of ultrasound energy from intervening bones and tissue, as well as 
motion and consistency of the targeted ventricular septum.  Flanking injury, comparable to that 
seen in ASD creation in the open-chest canine model [1], was also observed and likely related to 
some of the same factors.  These variables should be de-emphasized with an unobstructed 
acoustic window, such as the subcostal approach in human neonates, targeting of the thinner and 
less mobile atrial septum, as well as with improved transducer design allowing for motion 
tracking, ECG gating, and improved targeting (by decreasing focal distance and improving 
imaging resolution).   
Six additional animals were treated noninvasively with histotripsy to create VSDs and 
allowed to recover for 1 month. These animals had no clinical symptoms and gained weight 
appropriately. In addition, ventricular systolic function was preserved, and no evidence of 
thromboembolic events was observed based on lung pathology and MRI of the brain. The lack of 
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embolic events is consistent with in vitro data, showing that most particles created by histotripsy-
induced tissue fractionation are less than 6 μm in size (size of a red blood cell) [2]. In all, 
although more robust evaluation of other distal tissues is necessary before clinical advancement, 
the aforementioned data suggest that histotripsy cardiac therapy is safe and that effects are 
limited to the targeted region. Flanking hemorrhage and myocyte injury observed in the animals 
killed immediately after the procedure were completely resolved by 1 month, with some lesion 
expansion but suggesting that the unintentional damage was recoverable. However, the smallest 
amount of acute unintentional damage, such as the mild right ventricular free wall damage seen 
in two acute animals, could be devastating. This damage likely resulted from the close proximity 
of the free wall to the target, the bubble cloud size, and motion. Thus, innovative efforts to 
incorporate ultrafast motion tracking, to decrease aberration from intervening tissues (i.e., bones), 
and to synchronize real-time color-Doppler feedback would be useful to increase therapy 
accuracy further and decrease unintended injury. This work, in combination with previous data 
demonstrating effective creation of ASDs in an open-chest dog model suggest that non-invasive 
creation of both atrial and ventricular septal defects via histotripsy is potentially feasible in the 
human neonate. 
The effects of unintended injury during histotripsy therapy of the heart could be severe, 
and the risk of unintended injury is increased when the target and surrounding tissue are in 
motion. To mitigate this potential risk, a motion correction scheme was integrated into a 
histotripsy system to track the motion of a cardiac target during histotripsy therapy. Results 
indicate that the block matching method using diamond search algorithm and Kalman filtering is 
capable of tracking fast motion with high accuracy. When treating a moving target in vitro, 
significant improvement in therapy accuracy and efficiency was achieved compared to therapy 
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without using the algorithm. Though in vitro testing phantoms could not produce the non-rigid 
motion present in the heart, feasibility was evaluated in a live beating heart in vivo with further 
work necessary to quantitatively evaluate the system performance in this setting and adapt the 
system for non-invasive therapy. 
Real-time imaging feedback during minimally invasive or non-invasive ablation therapy 
is essential for ensuring efficient and thorough treatment of the target tissue. A new technique for 
histotripsy therapy feedback would be useful over existing techniques if it; didn’t require MRI 
compatible hardware, was more sensitive to early stage fractionation than ultrasound backscatter 
reduction, and could be done without halting therapy as is required for shear-wave elastography. 
It was shown that histotripsy pulses generate a consistent push at the therapy focus, and 
characteristics of the resulting motion can be accurately estimated using standard color Doppler 
acquisitions. The tissue response to this push changes significantly as the tissue is fractionated by 
histotripsy, and these changes can be quantified by color Doppler feedback metrics that are 
closely related to the degree of tissue fractionation as indicated by reference metrics of tissue 
damage (e.g. RBC lysing and percentage of the structurally intact cell nuclei). Further analysis 
targeting a specific tissue and therapeutic endpoint, could refine these methods into a valuable 
feedback metric for cardiac or any other histotripsy therapy application. 
Several histotripsy therapy transducers with appropriate physical dimensions and acoustic 
parameters to precisely ablate cardiac tissue non-invasively in a human neonate were developed 
and tested. Initial prototypes yielded minimal success in preliminary in vivo studies targeting the 
atrial septum in a neonatal porcine model, owing mainly to difficulties associated with that 
animal model. Additional work to augment that model, or develop a new or supplemental model 
is required to prove feasibility for ASD creation in a human neonate with congenital heart 
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disease. To aid in this process, a final prototype transducer was developed and integrated into a 
complete ultrasound guided histotripsy therapy system optimized for this application. This 
complete therapy system includes expanded Ultrasonix SonixTouch ultrasound imaging system 
cart with integrated histotripsy therapy amplifiers and control hardware, a macro-positioning arm 
with 3 axis precision micro-positioner, and an integrated therapy probe with custom telescoping 
phased array imaging probe and sealed ultrasound coupling chamber. 
 
7.2 Future Work 
7.2.1 Establish Feasibility of Cardiac Histotripsy in Human Neonate  
Initial studies targeting the atrial septum in the neonatal porcine model have had little 
success due to the damage to pre- and post- focal lung tissue. Increased treatment times are 
necessary to perforate the more membranous atrial septum versus the muscular ventricular 
septum targeted in previous work. The lung is more sensitive to the effects of high intensity 
ultrasound, with the pressure threshold for damage reported to be less than 1 MPa peak negative 
pressure [3]. For this reason, the porcine model is sub-optimal, as the heart orientation forces an 
acoustic path with intervening lung tissue. 
The orientation of the heart in humans is different from the orientation of the heart in pigs. 
In humans, that walk upright, the long axis of the heart is closer to parallel with the long axis of 
the body Figure 7-1A. In pigs however, that walk on all fours, the long axis of the heart is nearly 
perpendicular to the long axis of the body Figure 7-1B [4]. 
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Figure 7-1: Heart orientation comparison between humans and pigs. In humans (A) the long axis 
of the heart is closer to parallel with the long axis of the body. In pigs however (B), the long axis 
of the heart is nearly perpendicular to the long axis of the body. 
This orientation results in the best acoustic window to the atrial septum in the human heart being 
subcostal, below the ribs, aimed up into the heart through the liver. Through this window, the 
septum is nearly perpendicular to the ultrasound propagation, with only liver and heart in the pre-
focal path (Figure 7-2A), and the aorta, esophagus, and spine in the proximal post-focal path 
(Figure 7-2B, [5]). 
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Figure 7-2: Panel A shows an ultrasound image taken in a human neonate through the subcostal 
with only liver and the heart in the ultrasound path to the atrial septum (circled in red), treatment 
would be from bottom to top. Panel B shows an image (image credit [5]) of a human newborn, 
with the pre- and post-focal regions of the atrial septum (circled in red) free from lung, therapy 
would propagate from the top to the bottom (also from below the image to above the image, 
since the slice is transverse). 
 To achieve a similar atrial septal orientation in the pig, treatment must come through a 
parasternal window through ribs, sternum and lungs Figure 7-3. 
 
Figure 7-3: CT image of pig chest (disregard arrows, photo credit [6]), showing intervening lung 
in the pre-focal therapy field (circled in red, top right) and post-focal field (circled in red, bottom 
left). Therapy through the parasternal window would be applied from top right to bottom left. 
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 Based on these results, the best route for proof of feasibility is to combine the results of 
testing in an augmented version of this model with in vitro testing in a human phantom. 
Augmentations to this model may include: the introduction of an artificial pleural effusion to 
displace overlying lung from the acoustic field, surgical removal of overlying ribs and lung 
tissue, and surgical implantation of a sound absorbing material to shield post-focal lung from 
ultrasound injury. 
Since direct action will be necessary to spare lung damage in this animal model, it must 
be shown that those steps will not be necessary in the human neonate. To prove this, we plan to 
construct a model human neonate phantom. This model will be based on 3D reconstruction of the 
anatomy of the human neonate from MRI and CT datasets. From these datasets, thresholds can 
be assigned and different tissues segmented from others. A preliminary 3D reconstruction of the 
ribs (yellow), lungs (green), and heart (purple) is shown in Figure 7-4. 
 
Figure 7-4: 3D reconstruction of the ribs (yellow), lungs (green), and heart (purple) of the human 
neonate from MRI and CT datasets. 
Appropriate materials for each of these tissue types will need to be determined and the phantom 
constructed. 3D printing is a likely candidate for the ribs, to form the complex shape and strength 
of the ribs. Materials commonly used for commercial ultrasound imaging phantoms should be 
useful to mimic overlying tissue like skin, liver and muscle. A damage indicating phantom as 
sensitive to ultrasound damage as lung will need to be developed as well, to ensure that 
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histotripsy will not damage the lungs in the human neonate. A reusable cartridge to house 
excised porcine or human atrial septum tissue or phantom at the position of the atrial septum in 
the phantom will also be required. 
  
7.2.2 Motion Tracking Extensions  
Chapter 4 demonstrates the improvements in accuracy and efficiency with the addition of 
axial motion correction in histotripsy therapy. These methods are not limited to 1D motion 
however, as the algorithm actually already tracks the 2D motion of the target object in the 
ultrasound imaging plane. Since the therapy transducer was only capable of steering along the 
therapy axis and it could be aligned with the intended target in vivo such that the only significant 
motion was along that axis, only that component of motion was corrected for in that work. 
Should another application require it, extension to 2D motion correction is straightforward with 
the use of a 2D phased array therapy transducer, and should be evaluated. 
Similarly, should full 3D motion correction be necessary, the extension of the techniques 
presented in this work to 3D is also possible. The first step in extending the current system to 3D 
is to adapt or acquire a 3D ultrasound imaging probe for use on the Ultrasonix SonixTouch 
imaging system. Several 3D imaging probes are compatible with this system, and should be 
evaluated for use in the desired application. With 3D image data available, the next step is to 
extend the motion tracking algorithm for 3D motion tracking. Extension of the key principles of 
our algorithm from the current 2D system to 3D motion tracking is straightforward. With 
ultrasound 3D volume data and a reference volume image of the target, a 3D block matching 
procedure would be very similar to the current 2D methods. The SAD metric, diamond search 
procedure, and Kalman filter all extend naturally for use on 3 dimensional data. Extending our 
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current 2D motion tracking algorithm to 3D necessitates faster 3D data collection than available 
with conventional 3D imaging transducers however, so as an alternative, two 2D images in 
orthogonal planes may be used to estimate 3D motion at a faster speed. In this case, extension 
would be much more straight-forward, since parallel implementations of the current algorithm 
could be run simultaneously on the two image planes with an additional weighted average 
between the redundant estimations of the axial component of motion from each image plane. In 
either case, increased computational complexity could potentially reduce frame rates. To combat 
this, processing hardware upgrades and computation parallelization should be explored to 
potentially offset these additional computation requirements. 
 
7.2.3 Investigation into the Mechanism of Bubble-induced Color Doppler Feedback 
The color Doppler feedback methods presented in Chapter 5 rely on bubble-induced 
motion after each histotripsy pulse at the therapy focus along the axis of propagation. The source 
of this motion is not fully understood at this time, though the experiments demonstrate that the 
phenomenon is consistent and reproducible. Several potential mechanisms have been identified, 
and should be fully investigated.  
Acoustic radiation force is a tempting choice for the mechanism behind the type of push-
rebound motions observed in this study, however the extremely short pulses (< 2 cycles) are not 
sufficient to generate the observed motion simply through absorption alone. Moreover, 
preliminary experiments using particle image velocimetry (PIV) of embedded 10 micron glass 
beads show no measurable focal velocity at slightly sub-cavitation threshold pulses (~28.7 MPa 
peak negative pressure) with large velocities comparable to those observed in this study for 
supra-threshold pulses (~38.6 MPa peak negative pressure).  
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Figure 7-5: Velocity response measured using PIV for 4 peak negative focal pressures (left 
panel), and the mean peak velocity versus peak negative pressure from those measurements 
(right panel). 
This does not completely eliminate acoustic radiation force however, as the presence of 
forming cavitation bubbles could greatly enhance the radiation force via reflection of subsequent 
acoustic energy. The effects of the acoustic energy after the primary negative half-cycle could be 
potentially isolated using frequency compounding techniques [7]. Using this transducer, a single 
cycle pressure waveform can be generated at the transducer focus with either the positive half-
cycle after the negative half-cycle (Figure 7-6 left panel), or the positive half-cycle before the 
negative half-cycle (Figure 7-6 right panel). Comparing the resulting push velocity between the 
two scenarios should clarify the role of acoustic radiation force in generating this motion. 
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Figure 7-6: Synthesized pressure waveforms from the frequency compounding transducer with 
the positive half cycle after the negative half-cycle (left panel), or the positive half-cycle before 
the negative half-cycle (right panel). 
Another potential mechanism is asymmetric expansion of the bubbles during the 
formation of the bubble cloud. Preliminary studies using ultra high speed imaging (5 MHz, 200 
ns between frames) have shown that as the individual bubbles form, they grow more along the 
direction of propagation than back toward the therapy transducer. This is equivalent to a bubble 
moving through the medium, and thereby exerts a net forward force on the medium. Figure 7-7 
shows a series of 16 images of a single bubble taken immediately following the arrival of the 
histotripsy pulse at the focus (therapy pulse traveled from top to bottom). This is most obvious in 
frames 2-5, were the bubble has clearly translated along the path of therapy propagation at very 
high speed (> 50 m/s). 
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Figure 7-7: Ultra high speed images of a histotripsy bubble growth. These 16 images were 
acquired with 200 ns inter-frame delay (5 MHz) with 5 ns exposures. The spatial resolution is 
0.85 micron/pixel. 
The velocity of single bubbles in these images was computed by the change in position of the 
centroid, proximal and distal sides of bubbles from frame to frame divided by the inter-frame 
time. The average velocities of the centroid of the bubbles (left) and the proximal and distal sides 
of the bubbles (right) are shown in Figure 7-8. From the average velocity of the centroids, the 
bubbles appear to move rapidly away from the therapy, followed by damped rebound oscillations. 
From the plots of the velocity of the proximal and distal sides of the bubbles, the motion is more 
complicated. At the first time point, the distal side is moving rapidly away while the proximal 
side as nearly zero velocity. This is consistent with a bubble growing only forward. At the 
second time point, the distal side of the bubble is moving away from the therapy, but now the 
proximal side is moving away faster. This is consistent with a bubble shrinking in radius as it 
moves forward. For the next 2 time points, the distal side moves away and the proximal side has 
nearly zero velocity, consistent with the bubble growing forward again. Beyond this, there is 
 152 
 
alternating shrinking and growing of the bubble on top of the average oscillatory motion of the 
bubble observed in the centroid motion plot. 
 
Figure 7-8: Average frame to frame velocity of the proximal and distal sides of the histotripsy 
bubbles. Negative velocity is down in the images, along the direction of therapy propagation. 
The cumulative effect of this impulse-like push on all the bubbles could generate the motion 
observed in the color Doppler study. Additional work is necessary however, to link this motion 
during cloud formation to the motion detected after cloud collapse.  
The violent collapse of the histotripsy bubble cloud is another potential mechanism that 
could generate the observed motion. The bubble cloud collapse certainly generates significant 
motion in the focal region, and this was observed in this study. This motion appeared 
inconsistent from pulse to pulse however, and is unlikely to cause the consistent and predictable 
push and rebound motion along the axial direction of the transducer. An experiment to test this 
decisively will need to be designed to be sure however. Some combination of these mechanisms 
is also possible, and a comprehensive study should be designed, based on these preliminary 
results to fully elucidate the mechanism behind this observed motion. 
 
0 0.5 1 1.5 2 2.5 3
-250
-200
-150
-100
-50
0
50
100
Average Velocity of Bubble Centroids
Time (sec)
V
el
oc
ity
 (m
/s
ec
)
0 0.5 1 1.5 2 2.5 3
-250
-200
-150
-100
-50
0
50
100
Time (sec)
V
el
oc
ity
 (m
/s
ec
)
Average Velocity of Proximal and Distal Bubble Walls
 
 
Proximal Side
Distal Side
 153 
 
7.3 References 
[1] Z. Xu, G. Owens, D. Gordon, C. A. Cain, and A. Ludomirsky, "Noninvasive Creation of 
an Atrial Septal Defect by Histotripsy in a Canine Model," Circulation, vol. 121, pp. 742-
749, February 2010. 
[2] Z. Xu, Z. Fan, T. L. Hall, F. Winterroth, J. B. Fowlkes, and C. A. Cain, "Size 
Measurement of Tissue Debris Particles Generated from Pulsed Ultrasound Cavitational 
Therapy – Histotripsy," Ultrasound in Medicine & Biology, vol. 35, pp. 245-255, 2009. 
[3] S. Z. Child, C. L. Hartman, L. A. Schery, and E. L. Carstensen, "Lung damage from 
exposure to pulsed ultrasound," Ultrasound in Medicine & Biology, vol. 16, pp. 817-825, 
1990. 
[4] S. J. Crick, M. N. Sheppard, S. Y. Ho, L. Gebstein, and R. H. Anderson, "Anatomy of the 
pig heart: comparisons with normal human cardiac structure," J Anat, vol. 193 ( Pt 1), pp. 
105-19, Jul 1998. 
[5] R. Walmsley and W. S. Monkhouse, "The heart of the newborn child: an anatomical 
study based upon transverse serial sections," J Anat, vol. 159, pp. 93-111, Aug 1988. 
[6] A. Lembcke, T. H. Wiese, J. Schnorr, S. Wagner, J. Mews, T. J. Kroencke, C. N. 
Enzweiler, B. Hamm, and M. Taupitz, "Image quality of noninvasive coronary 
angiography using multislice spiral computed tomography and electron-beam computed 
tomography: intraindividual comparison in an animal model," Invest Radiol, vol. 39, pp. 
357-64, Jun 2004. 
[7] K.-W. Lin, T. L. Hall, R. J. McGough, Z. Xu, and C. A. Cain, "Synthesis of Monopolar 
Ultrasound Pulses for Therapy: The Frequency-Compounding Transducer," IEEE Trans 
Ultrason Ferroelectr Freq Control, accepted Jan. 2014. 
 
 
